The epidemiology of Gram negative bacteraemia at Tygerberg Hospital by Paterson, Lauren Ann
The epidemiology of Gram negative 
bacteraemia at Tygerberg Hospital 
Lauren Ann Paterson 
Thesis presented in partial fulfilment of the requirements for the degree Master of 
Science in Medical Microbiology in the Faculty of Medicine and Health Sciences at 
Stellenbosch University 
Supervisor: Prof AC Whitelaw 
Co-supervisor: Dr M Newton-Foot 
Division of Medical Microbiology, Department of Pathology 
March 2018
i 
Declaration 
By submitting this thesis electronically, I declare that the entirety of the work 
contained therein is my own, original work, that I am the sole author thereof (save to the 
extent explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch 
University will not infringe any third party rights and that I have not previously in its entirety 
or in part submitted it for obtaining any qualification. 
Date: March 2018 
Copyright © 2018 Stellenbosch University 
All rights reserved 
Stellenbosch University  https://scholar.sun.ac.za
ii 
 
Summary 
Background 
Escherichia coli and Klebsiella pneumoniae are common causes of Bloodstream Infections 
(BSI). β-lactam antibiotics, such as cephalosporins and carbapenems, are commonly used 
to treat these infections. Increasing resistance has been noted, usually due to plasmid 
mediated β-lactamases such as Extended-Spectrum β-lactamases (ESBLs) and 
carbapenemases. This study describes the antibiotic resistance profiles, outcomes and 
epidemiology of Gram negative BSIs in a tertiary hospital in Cape Town, South Africa. 
Methods 
Patients with E. coli (n=70) and K. pneumoniae (n=70) bacteraemia identified at Tygerberg 
Hospital between April 2015 and March 2016 were included. Identification and Antibiotic 
Susceptibility Testing (AST) were performed as part of routine testing. Patient data was 
obtained through record review. ESBL and carbapenemase genes were characterised by 
Polymerase Chain Reaction (PCR) and DNA sequencing. Isolates were typed using rep-
PCR and Pulsed Field Gel Electrophoresis (PFGE). Chi-square and Mann-Whitney tests 
were used to estimate significance of correlation. 
Results and discussion 
45% of patients were male, and 30.7% were paediatric. 66.4% of BSI were hospital-
acquired. K. pneumoniae accounted for 61.3% of hospital-acquired isolates; 72.3% of 
community-acquired isolates were E. coli. 55.7% of K. pneumoniae and 15.7% of E. coli 
were cephalosporin resistant (presumed ESBL); one K. pneumoniae isolate was 
carbapenem resistant. Increased antibiotic resistance and ESBL production was seen in 
hospital-acquired isolates.  
ESBL genes were harboured in 35.7% of isolates; 50.7% contained β-lactamase genes and 
13.6% no β-lactamase genes. Most TEM genes (98%) were β-lactamases; 47.4% of SHV 
genes were β-lactamases, 7% were ESBLs and 45.6% were SHV genes whose spectrum is 
uncertain. Isolates containing SHV genes with uncertain spectrum were phenotypically 
susceptible to cephalosporins, suggesting these enzymes do not have extended-spectrum 
activity. Multiple β-lactamase genes were present in 60% of K. pneumoniae isolates, and 
only 5.7% of E. coli isolates. CTX-M genes were the most common ESBL genes, with most 
(91.3%) of these belonging to group 1. CTX-M genes were found in combination more often 
than not (84.8%). No carbapenemase genes were detected.  
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Molecular and phenotypic resistance agreed in 95.3% of isolates. The 30-day mortality rate 
was 30%, with no association between mortality and hospital-acquired infection, or with 
ESBL production (phenotypic or molecular). Molecular and phenotypic resistance was 
associated with hospital-acquired isolates (P=0.001, P<0.001). 
Both strain typing techniques showed substantial diversity among isolates, with minimal 
clustering; which suggests multiple clones in the hospital, precluding any possibility of 
assessing associations. 
Conclusion 
Increased resistance was observed in hospital-acquired isolates, and the association 
between hospital-acquired isolates and ESBL presence was significant, which is not 
unexpected. Isolates were genetically diverse and showed minimal clustering, suggesting 
that resistance may be due to horizontal transmission. Continuous efforts towards 
surveillance of the epidemiology and resistance patterns of circulating strains are required to 
monitor and guide antimicrobial stewardship, infection prevention and control (IPC) practises 
and empiric therapy.  
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Opsomming 
Agtergrond 
Escherichia coli en Klebsiella pneumoniae is alombekend om bloedstroominfeksies (BSI) te 
veroorsaak. Hierdie infeksies word grotendeels behandel met β-laktam antibiotika, soos 
kefalosporiene en “carbapenems”, Verhoogde β-laktam antibiotika weerstandigheid word 
toegeskryf aan  plasmied-gemedieërde β-laktamases soos die “Extended-Spectrum  
β-lactamases” (ESBLs) en “carbapenemases”. Hierdie studie beskryf die antibiotiese 
weerstandsprofiele, uitkomste en epidemiologie van Gram negatiewe BSI’s in ‘n tersiêre 
hospitaal in Kaapstad, Suid-Afrika. 
Metodes 
E. coli (n=70) en K. pneumoniae (n=70) bakterieë vanaf kliniese monsters van Tygerberg 
Hospitaal tussen April 2015 en Maart 2016 was ingesluit. Spesie-identifikasie en 
antibiotiese-vatbaarheidstoetse was uigevoer as deel van roetine toetse. Pasiënt data was 
deur middel van mediese rekords verkry. ESBL en carbapenemase gene is met 
polimerasekettingreaksie (PKR) en DNA-volgordebepaling gekarakteriseer. Isolate is 
getipeer met rep-PKR en “Pulsed Field Gel Electrophoresis” (PFGE). Chi-kwadraat en  
Mann-Whitney toetse was toegepas om die statistiese betekenisvolheid van korrelasie te 
skat. 
Resultate en bespreking 
45% van pasiënte was manlik en 31.4% was pediatries. 66.4% van BSI was hospitaal-
geassosieerd. 61.3% van die hospitaal-geassosieerd isolate was K. pneumoniae; 72.3% van 
die gemeenskaps-geassosieerde isolate was E. coli. 55.7% van K. pneumoniae en 15.7% 
van E. coli was kefalosporien-weerstandig (veronderstelde ESBL); een K. pneumoniae 
isolaat was carbapenem-weerstandig. ‘n Toename in antibiotiese weerstandiheid en ESBL-
produksie was waargeneem in die hospitaal-geassosieerd isolate. 
ESBL gene was teenwoordig in 35.7% van die isolate; 50.7% bevat β-laktamase gene en 
13.6% bevat geen β-laktamase gene nie. TEM gene (98%) was grotendeels β-laktamases; 
47.4% van die SHV gene was β-laktamases, 7% was ESBL en 45.6% was SHV gene 
waarvan die spektrum onbekend was. Isolate met SHV gene met onbekende spektrums was 
fenotipies vatbaar vir kefalosporiene, wat voorstel dat hierdie ensieme nie uitgebreide 
spektrum aktiwiteit gehad het nie. Verskeie β-laktamase gene was teenwoordig in 60% van 
K. pneumoniae isolate en 5.7% E. coli isolate respektiewelik. CTX-M gene was die mees 
algemeen ESBL gene en die meerderheid (91.3%) behoort aan groep 1, wat die 
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wêreldbekende CTX-M (CTX-M-15) bevat. CTX-M gene was grotendeels waargeneem in 
kombinasie (84.8%). Geen carbapenemase gene was gevind nie.  
Molekulêre en fenotipiese weerstandigheid het in 95.3% van die isolate ooreengestem. Die 
30-dag mortaliteit was 30%, met geen assosiasie tussen hospitaal-geassosieerde infeksie, 
of met ESBL produksie (molekulêr of fenotipies) nie. Molekulêre en fenotipiese 
weerstandigheid was geassosieer met hospitaal-geassosieerde isolate (P=0.001; P<0.001). 
Beide tiperingstegnieke het aansienlike diversiteit bevestig tussen die isolate met minimale 
groepering. Dit dui daarop dat verskeie klone voorkom in die hospitaal, en dat enige 
moontlikheid om die assosiasies tussen tipe, weerstands-fenotipe of -genotipe of uitkoms 
bepaal kan word.  
Gevolgtrekking 
‘n Toename in weerstandigheid was waargeneem in alle hospitaal-geasosieerde isolate. Die 
assosiasie tussen hospitaal geasosieerde islolate en die teenwoordigheid van ESBL’s was 
statisties relevant. Isolate was geneties divers en het minimale groepering in identiteit 
vertoon, dit stel voor dat die verspreing horisontaal plaas kon gevind het. Verdere navorsing 
in epidemiologie en weerstandigheids patrone van verspreidende stamme is noodsaaklik om 
antimikrobiese verhoudings, infeksie beheer en empiriese terapie te kan bevorder. 
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Chapter 1: Literature review 
1.1 Antimicrobial resistance: an overview 
Bacterial infections affect numerous people worldwide, including South Africans. Antibiotics 
have decreased the burden of bacterial infections and have become heavily relied upon 1. 
There has been a notable increase in antibiotic resistance in bacteria and unfortunately, the 
growing resistance far outpaces the development of new therapies 2. Drug resistance 
presents a treatment problem, as many bacteria have acquired one or more resistance 
mechanism. These strains are problematic due to the fact that they harbour multiple 
resistance genes encoding resistance to more than one type of antibiotic. Infections with 
these bacteria are difficult to treat due to the reduced number of treatment options 3.  
The antimicrobial resistance rates vary widely across the globe, depending on the bacterial 
species, antibiotic group and location 4. Many studies world-wide have cited an increase in 
resistance to third generation cephalosporins and carbapenems 4–6. The increasing 
prevalence of resistance and multi-resistant bacteria has led to the use of combination 
therapies, expensive second-line antibiotics and older antibiotics, such as colistin, that are 
less appealing due to high levels of toxicity 7. This may then place selective pressure on the 
bacteria and select for colistin resistant isolates, further exacerbating the resistance problem. 
Plasmid-mediated colistin resistance has already been cited and this is cause for great 
concern as the options for treatment are running out and development of  truly pan-resistant 
bacteria may soon become a reality 8. Expensive second-line antibiotics are not commonly 
used in low- and middle-income countries due to their cost, resulting in increased morbidity 
and mortality in these countries 1.  
Extended-Spectrum β-lactamase (ESBL) producing bacteria were originally considered to be 
only healthcare-associated as infections and outbreaks of this organism were only seen in 
these settings. However, bacteria carrying these resistance mechanisms are becoming more 
common in community settings and have been seen in patients without previous exposure to 
healthcare settings 9.  
Antibiotics are often overused, creating increased selection pressure for resistant bacteria 
and driving the evolution of resistance 10. Studies have shown a link between antibiotic 
consumption and the emergence of resistant strains 10.  A study by Van Boeckel et al. looked 
at antibiotic consumption from 2000 to 2010 by analysing pharmaceutical sales data, and 
found that consumption of antibiotics increased by 35% over the investigated time period 1. 
The largest absolute increase in consumption was observed in cephalosporins, broad-
spectrum penicillins and fluoroquinolones; additionally cephalosporins and broad-spectrum 
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penicillins constituted 55% of the total antibiotics consumed 1. They also noted significant 
increases in the use of carbapenems (45%) and polymyxins (13%) such as colistin 1. This 
study also noted that consumption of antibiotics increased considerably in developing 
countries, with the highest rates being seen in the BRICS (Brazil, Russia, India, China, and 
South Africa) countries and French West Africa 1. Distressingly, 76% of overall increase in 
global antibiotic use was attributed to the BRICS countries 1. 
Other factors which contribute to antimicrobial resistance include the over the counter sale of 
antibiotics in some countries, self-medication with these drugs, non-adherence to the 
treatment recommended by doctors, which is common in Africa, and incorrect or 
unnecessary prescribing of antibiotics 10,11.  
Antibiotics are extensively used in agriculture, particularly in livestock 10. These antibiotics 
are used to promote growth and prevent infection, producing larger yields and higher quality  
product 10. It is estimated that as much as 80% of the antibiotics sold in the United States of 
America are used by the livestock industry 10. These antibiotics are ingested by humans 
when they consume these animal products, thereby increasing selection pressure within 
humans for antibiotic resistant bacteria 10. Antibiotics are also excreted by animals in stool 
and urine, which along with the spraying of antibiotics on crops results in higher 
concentrations of antibiotics in the environment 10. 
Several factors have been associated with increased risk of infection with an antibiotic 
resistant pathogen, including previous antibiotic use, recent or current hospitalisation, 
immunosuppressive drugs or disease, hospital overcrowding and international travel 11,12.  
Infections with resistant organisms are costlier as patients have longer hospital stays and 
need expensive antibiotics. These infections may also result in prolonged exposure to 
invasive medical devices and procedures, affecting patient morbidity and further prolonging 
time spent in hospital. The hospitals need to spend money decontaminating the area when 
patients are infected with resistant bacteria, and ensure extra care is taken to prevent the 
spread of these resistant organisms to other patients. The increased prevalence of 
resistance combined with the absence of new antibiotics has resulted in improved efforts 
towards infection control as well as antibiotic stewardship 13. The efficacy of antibiotics 
needs to be maintained so that we can continue to prevent infection in immunosuppressed 
patients and when performing invasive surgery and to treat bacterial infections 10. 
Antimicrobial resistance has been described in a wide range of organisms, with increasing 
resistance in Enterobacteriaceae being of particular concern. Infection with these bacteria is 
frequent and development of multiple resistance mechanisms has seen therapeutic options 
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dwindling. Prevention of infections with Enterobacteriaceae may be particularly difficult as 
these bacteria are found in many environments and form part of the human microflora 14.  
1.2 Enterobacteriaceae 
Enterobacteriaceae are one of the largest groups of clinically important Gram negative 
bacilli. These organisms can be found in many environments, such as soil and water and 
also form part of the intestinal flora of various animals, including humans 14. Clinically 
important species in this family include Escherichia coli, Proteus mirabilis, Klebsiella 
pneumoniae, Shigella spp. as well as Salmonella spp. This heterogeneous group of bacteria 
range from commensals to obligate pathogens. Some members of the Enterobacteriaceae 
family, such as E. coli, form part of our normal flora and usually only cause disease in 
immunocompromised hosts. Others such as Shigella spp., are always associated with 
disease, i.e. obligate pathogens 14. 
Enterobacteriaceae are a common cause of community- and healthcare- acquired infections, 
including Bloodstream Infections (BSI), Urinary Tract Infections (UTI), respiratory and wound 
infections 14,15. Among the Enterobacteriaceae, E. coli and K. pneumoniae are frequently 
associated with bloodstream infections and commonly harbour β-lactam resistance 
mechanisms 16,17. 
E. coli consists of a large diverse group of bacteria which occur naturally in the human 
gastro-intestinal tract. Most strains of E. coli are not known to cause illness in heathy hosts, 
although some strains are pathogenic and can cause serious illnesses, as a result of various 
virulence factors. Pathogenic E. coli may cause a variety of illnesses such as diarrhoea, 
UTIs, and pneumonia. E. coli is a common cause of bacteraemia and a major causative 
agent of food-borne illnesses 4. E. coli is usually transmitted through ingestion of 
contaminated food, person-to-person contact, animal contact or contact with environments 
that are contaminated with faecal matter 18.  
K. pneumoniae is said to be the most clinically relevant species within the Klebsiella genus 
as it is responsible for the majority of infections caused by Klebsiella species 19. Klebsiella is 
often found in the gut of humans and animals and is known to be a cause of opportunistic 
infections in compromised hosts 20. K. pneumoniae is frequently isolated in hospitals and has 
a notable ability to survive on hands, which facilitates its spread 19,20. This species of bacteria 
often carries resistance genes such as β-lactamases, ESBLs and carbapenemases 21,22. 
This characteristic makes infections with these bacteria more concerning and difficult to 
treat.   
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1.3 Bloodstream infections  
Bloodstream infection (BSI), or bacteraemia, is defined as the presence of viable bacteria in 
the blood 23,24. It is a major source of morbidity and death with mortality rates ranging from 
10 to 70% 17,23,25,26. A systemic review estimates bacteraemia to be amongst the top seven 
causes of death in European and North American countries, with 2 million episodes and 
250 000 fatalities annually 27.  
Bacteraemia may arise as a primary infection, or secondary to an infection at a defined 
anatomical site (e.g. urinary tract, lower respiratory tract) 25. Patients who are 
immunocompromised or critically ill have an increased risk of developing a BSI 23. BSIs can 
be classified into community- or hospital-acquired based on where the infection was 
contracted 28. Studies have found that the different types of BSIs can differ in epidemiology, 
severity and mortality rate 17,23. Sepsis arises when there is a systemic response from the 
host to the BSI 29. This is characterised by increased heart and respiratory rate,  elevated 
white blood cell count as well as an abnormally high or low body temperature 23. 1.8 million 
cases of sepsis are reported every year, although this most likely an underestimation due to 
lack of reporting 23. 
Over time, the aetiology of BSIs has changed; from Gram negative bacteria to Gram positive 
in the 1990s, and recently Gram negative bacteria have re-emerged as the predominant 
source of BSIs 28,30. Enterobacteriaceae in particular are presently one of the major causes 
of BSIs 28. 
Healthcare-associated infections have a higher incidence rate (at least double) in low 
income settings compared to high income settings 31. African studies reported a prevalence 
of 15,5 patients per 100 compared to 7,1 reported by European studies and 4,5 reported by 
studies conducted in the United States of America. It has been estimated that healthcare-
associated bacteraemia is the cause of 25 000 deaths of African children each year 32. 
E. coli and K. pneumoniae are two major agents implicated in the cause of BSIs 33. A study 
done in 2012 at Groote Schuur Hospital in South Africa, found that E. coli and  
K. pneumoniae were the most common Gram negative bacteria causing bacteraemia 17. A 
retrospective study done at Tygerberg Hospital in South Africa described BSIs in paediatric 
patients from 2008 to 2013 32. This study found that Gram negative bacteraemia dominated, 
with K. pneumoniae and E. coli being the most common Gram negative pathogens. The 
study also described an association with healthcare-associated bacteraemia and Gram 
negative pathogens as well as a higher antimicrobial resistance in bacteria causing 
healthcare-associated bacteraemia. BSIs with Gram negative bacteria were associated with 
higher mortality, as observed in other studies carried out in Africa 34,35.  Concerningly, this 
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study observed a high rate of antimicrobial resistance among community-associated 
bacteria, particularly in K. pneumoniae and E. coli. 
A study conducted on Kenyan children found that healthcare-associated BSIs had a 
mortality rate of 53%, compared to 24% in community-acquired BSIs 35. They also observed 
a higher mortality rate when bacteraemia was caused by Gram negative bacteria, 61%, 
versus 38% for Gram positive infections.  
It is necessary to identify the bacteria responsible for the BSI in order to effect appropriate 
treatment. These bacteria are usually identified by blood culture, as this is the current gold 
standard 23. Blood from the patient is inoculated into the appropriate culture medium and 
incubated. This technique takes between 24 and 72 hours to obtain cultures and additional 
time to identify the bacterium and obtain the antibiogram, depending on the testing platform 
used. For this reason, empiric treatment is often relied on until more information is available, 
however some countries rely on empiric treatment alone if diagnostic facilities are not 
available 36. The emergence and spread of various antibiotic resistance mechanisms has 
made the treatment of BSIs increasingly difficult and detrimental to patients 37. This is 
because patients are often given incorrect empirical treatment leading to increased morbidity 
and mortality, especially when causative bacteria harbour resistance mechanisms such as 
ESBLs and carbapenemases 38. It is therefore important to have current information 
regarding the epidemiology of circulating pathogens as well as their resistance rates.  
1.4 β-lactam antibiotics 
Infections with Enterobacteriaceae are usually treated using β-lactam antibiotics. β-lactams 
are a large group of antibiotics, which are all characterised by a β-lactam ring. These 
antibiotics are one of the oldest and most widely used antibiotic families 18,39. The different 
groups within this family are distinguished by the structure of additional rings attached to the 
β-lactam ring 20. Antibiotics in this group include penicillins, monobactams, cephalosporins 
and carbapenems. Table 1.1 summarizes the different classes of β-lactams.
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Table 1.1: The different classes of β-lactam antibiotics and some of their properties  
(Adapted from Versalovic (2011) 18 & Vasconcillos (2010) 40) 
 
β-lactams act on a vital component of the bacterial cell, the cell wall. Specifically, they bind 
to enzymes called Penicillin-Binding Proteins (PBPs) which form an integral part of cell wall 
construction. These enzymes facilitate the final cross-linking of cell wall structures  
N-acetylmuramic (NAM) acid and N-acetylglucosamine (NAG); these two molecules form the 
building blocks of peptidoglycan and they form a rigid mesh which gives the cell wall its 
strength 14. Binding of β-lactams to these enzymes results inhibition of cross-linkage and 
leads to the loss of the cell wall’s integrity, ultimately leading to cell lysis 39. β-lactams may 
also have a bactericidal effect by triggering autolytic enzymes in the cell envelope due to 
accumulation of cell wall precursors 41.  
Penicillins were some of the first antibiotics discovered, changing the treatment of infections. 
Penicillins consist of a thiazolidine ring attached to a β-lactam ring 41. While they are 
naturally synthesized by many Penicillium spp., many semi-synthetic variations are also 
manufactured 41. Penicillins are active against many Gram positive bacteria, and have some 
Class Penicillins 
(penams) 
Cephalosporins 
(cephems) 
Carbapenems 
(penems) 
Monobactams 
Core 
structure 
 
 
 
 
 β-lactam ring fused 
to a thiazolidine 
ring. 
β-lactam ring fused 
to a dihydrothiazine 
ring. 
β-lactam ring fused 
to a hydoxyethyl 
side chain. 
β-lactam ring with 
various side-chains. 
Spectrum 
of activity 
Most Gram positive 
and some Gram 
negative and 
anaerobic 
organisms. 
Grouped by 
generations based 
on their activity. 
Third generation 
(broad spectrum) 
are less active than 
first against Gram 
positive cocci but 
are more active 
against 
Enterobacteriaceae 
and P. aeruginosa.  
Widest spectrum. 
Excellent activity 
against Gram 
positive species. 
Most potent  
β-lactam against 
anaerobes.  
Active against 
aerobic Gram 
negative bacteria, 
including  
Enterobacteriaceae. 
Examples Ampicillin 
Cloxacillin 
Amoxicillin 
Cefotaxime 
Cefepime 
Ceftazidime 
Imipenem 
Meropenem 
Ertapenem 
Aztreonam 
Tigemonam 
Tabtoxin 
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limited activity against Gram negative bacilli. Examples of these antibiotics include ampicillin 
and amoxicillin.  
Monobactams are monocyclic β-lactams that consist of a single β-lactam ring with various 
attached side chains 41. They are narrow spectrum antibiotics which target aerobic Gram 
negative bacteria 42. Monobactams are stable against most plasmid and chromosomally 
mediated β-lactamase enzymes which hydrolyse β-lactam antibiotics 42. Currently, 
aztreonam is the only monobactam in clinical use 41.  
Cephalosporins are a group of β-lactams characterised by a six membered dihydrothiazine 
ring attached to the β-lactam ring 41. Antibiotics in this group can be further classified into 
different generations (first to fifth) based on their spectrum of activity and stability against  
β-lactamases 43,44. First generation cephalosporins, such as cefazoline, display activity 
focused on Gram positive bacteria. Second generation cephalosporins maintain activity 
against Gram positive cocci, but they have increased activity against Gram negative bacilli. 
Cefoxitin is an example of a second generation cephalosporin. Third generation 
cephalosporins demonstrate a considerable increase in activity against Gram negative 
bacilli, however some members have decreased action against Gram positive cocci. 
Commonly used cephalosporins of this generation include cefotaxime and ceftazidime. 
Agents classified as fourth generation cephalosporins have the widest spectrum of activity 
including most Gram negative bacilli and Gram positive cocci. These cephalosporins are 
also less susceptible to hydrolysis by β-lactamases. A well-known example of a fourth 
generation cephalosporin is cefepime. Third and fourth generation cephalosporins are 
considered to be extended-spectrum cephalosporins. The fifth generation cephalosporins, 
such as ceftaroline, are active against methicillin resistant staphylococci and also have 
broad-spectrum activity against Gram negative bacteria 44.  
Penicillins and some cephalosporins are often combined with β-lactamase inhibitors to 
increase their activity against Gram negative bacilli, particularly those producing  
β-lactamases. β-lactamase inhibitors alone are weakly bactericidal but form a good adjuvant 
when combined with β-lactam antibiotics. This is due to their ability to breakdown  
β-lactamases, which prevents the hydrolysis of the β-lactam antibiotic, thereby retaining the 
activity of the β-lactam antibiotic despite the presence of a β-lactamase 44,45. Examples of  
β-lactamase inhibitors include clavulanic acid, sulbactam and tazobactam. Examples of 
commonly used β-lactam-β-lactamase inhibitors include piperacillin-tazobactam and 
amoxicillin-clavulanate. These are a good carbapenem-sparing treatment option 45.  
Carbapenems are said to be one of the most important β-lactam antibiotics due to their 
broad spectrum of activity and high potency 46. This is due to their efficient penetration 
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though the bacterial outer membrane as well as their high affinity for PBPs 44. This group has 
a five membered ring attached to the β-lactam ring but it differs structurally from other  
β-lactams by its hydroxyethyl side chain 41. This antibiotic is usually used to treat patients 
infected with multi-resistant organisms, as it is less affected by certain resistance 
mechanisms, including β-lactamases 47. This is as a result of the antibiotic’s unique structure 
18. Commonly used carbapenems include imipenem, meropenem and ertapenem 48.  
1.5 β-lactam resistance 
Bacteria often develop strategies to persist in the presence of antibiotics. This is a natural 
phenomenon in bacteria, but is accelerated by the increased use of antibiotics in humans 
and animals through natural selection of resistant bacteria 49. These methods of resistance 
include antibiotic inactivation or modification (usually by enzymes), target alteration or 
preventing accumulation of the antibiotic inside the cell by decreasing permeability of the cell 
membrane/wall or increasing efflux 50. The emergence of these resistance mechanisms in a 
bacterial population is associated with certain factors, the most important of which being 
mutation rate, horizontal transmission of resistance genes and the fitness costs that these 
gene/s could impose on the bacterium 51. Increasing resistance in members of the 
Enterobacteriaceae family has resulted in multi-resistant and in some cases pan-resistant 
species i.e species resistant to all tested antibiotics. These once simple to treat organisms 
now pose a major problem as treatment options are considerably reduced due to increasing 
resistance 12.  
β-lactam resistance in Enterobacteriaceae is most often due to the production of  
β-lactamase enzymes. These enzymes confer resistance to β-lactam antibiotics by 
hydrolysing the chemical bonds within the antibiotic’s structure, specifically the bonds within 
the β-lactam ring 52 (Figure 1.1). This breaking of the β-lactam ring causes the loss of the 
activity or binding affinity of the β-lactam 18,52. β-lactamases also belong to the same family 
of serine proteases as PBPs 14.  
 
Figure 1.1: β-lactamase activity. β-lactamases hydrolyse β-lactam antibiotics which results in breaking 
of their β-lactam ring and consequently results in their loss of activity.  
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β-lactamases can be classified using two general schemes, the Ambler molecular 
classification scheme and the Bush-Jacoby-Medeiros functional classification system 22. The 
Ambler classification scheme separates β-lactamases into four major classes, A to D, based 
on amino acid homology. Classes A, C and D are made up of serine β-lactamases, while 
class B is made up of metallo-β-lactamases 22. The Bush-Jacoby-Medeiros classification 
scheme groups β-lactamases by their functional similarities. This scheme originally divided 
β-lactamases into 4 groups but has now been revised to 3 groups with multiple sub-groups 
53. While structural groupings like the Ambler scheme are simple and more objective, 
functional groupings assist in relating the enzyme’s properties to their clinical role 53.  
It has long been known that K. pneumoniae and E. coli produce β-lactamases, such as  
SHV-1 and TEM-1 respectively, which are able to hydrolyse amino-penicillins (such as 
amoxicillin and ampicillin), but not cephalosporins 9. The cephalosporins were specifically 
designed to withstand hydrolysis by these enzymes and overcome the β-lactamase 
mediated resistance.  9.  
1.5.1 Extended-spectrum β-lactamases 
Extended-Spectrum β-lactamases (ESBLs) are β-lactamases which are able to hydrolyse an 
extended-spectrum of β-lactamase antibiotics including penicillins, 1st-, 2nd- and  
3rd-generation cephalosporins and the monobactam, aztreonam. It is suggested that this 
resistance mechanism developed as a result of increased selection pressure due to the 
wide-spread use of extended-spectrum cephalosporins 54. The first published report of this 
type of β-lactamase was in 1983, and since then many other ESBLs have been discovered 
22. ESBLs have been found in a range of Enterobacteriaceae, but they are most common in 
K. pneumoniae and E. coli 55. Bacteria have developed two main approaches for the 
development of ESBLs, namely by the expansion of activity of β-lactamases and by 
acquiring genes encoding enzymes with ESBL activity, which can occur alone or in 
combination 56. Different families of ESBLs have been described based on amino acid 
sequences, and the most commonly detected and clinically significant ESBLs belong to the 
TEM, SHV and CTX-M families 57. 
TEM family 
All TEM-ESBLs are derivatives of the β-lactamases TEM-1 and TEM-2. The TEM family is 
named after Temoneira, the first patient from whom a β-lactamase producing bacterium was 
isolated 22, in 1965. TEM-ESBLs have developed as a result of amino acid substitutions 
which have altered their substrate profile and isoelectric point. Some amino acid residues 
along the blaTEM gene have been said to more important for changes to the enzyme’s 
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phenotype, particularly to create the ESBL phenotype 58. These changes can be seen in the 
figure below (figure 1.2).   
 
Figure 1.2: Amino acid substitutions in the TEM gene that are important to the ESBL phenotype. 
Adapted from Bradford (2001) 58. 
SHV family  
The SHV β-lactamases are named after the sulfhydryl variable. The progenitor of this family, 
SHV-1, is commonly found in K. pneumoniae 59. The first ESBL-SHV, SHV-2, was 
discovered when an SHV enzyme was found to hydrolyse a third generation cephalosporin, 
cefotaxime 58. Sequencing revealed a mutation resulting in a serine residue in place of a 
glycine at position 238. This mutation accounted for the extended-spectrum properties of this 
β-lactamase and is therefore found in the majority of blaSHV genes possessing an ESBL 
phenotype 58.  
CTX-M family 
The CTX-M family is a more recently discovered group of ESBLs, however they have 
disseminated worldwide and have quickly become the most prevalent ESBL 60. CTX-M 
ESBLs were named due to their preferential hydrolysis of the antibiotic cefotaxime 59.   
blaCTX-M genes are not closely related to blaSHV or blaTEM genes as they only show a 
40% sequence similarity 55,59. CTX-M ESBLs and β-lactamases of Kluyvera spp. are closely 
related and the adjacent gene sequences of both resistance genes also show similarity 59. 
This suggests that CTX-M genes originated in Kluyvera spp. and mobilised onto a mobile 
element facilitating their dissemination to other bacterial species. CTX-M ESBLs also differ in 
their preferred substrates, as TEM and SHV ESBLs preferentially hydrolyse ceftazidime, 
while CTX-M ESBLs prefer cefotaxime 9. 
CTX-M enzymes can be clustered into 5 sub-groups based on their amino acid sequences, 
namely CTX-M1, CTX-M2, CTX-M8, CTX-M9 and CTX-M25 (Figure 1.3) 60. These groups 
have been named after the first member in the group to be described 56. The amino acid 
homology of different CTX-M ESBL groups differs by 10% or more 9. CTX-M 15, belonging 
to group 1, has become the most commonly found CTX-M ESBL worldwide 9.  
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Figure 1.3: A tree diagram depicting the sub-groups of CTX-M enzymes 56. The branches represent 
the five sub-groups of CTX-M ESBLs. From left to right they are CTX-M-1, CTX-M-2, CTX-M-25, CTX-
M-8 and CTX-M-9. 
1.5.2 Carbapenemases 
Infections with ESBL producing organisms have a few treatment options, the most popular 
being β-lactam/β-lactamase inhibitor combinations and carbapenems 22. Carbapenems are 
becoming increasingly favoured, leading to increasing carbapenem use and subsequent 
selection pressure for carbapenem resistance 61,62. 
Bacteria may become resistant to carbapenems in a few ways, one of these being 
production of carbapenemases. This mechanism of resistance is potentially more concerning 
than the others, as it is more easily transferred to other bacteria via plasmids 63. Other 
carbapenem resistance mechanisms include permeability defects and efflux pumps, 
sometimes combined with increased expression of β-lactamase enzymes that have limited 
carbapenemase activity in isolation 19. Production of carbapenemases is considered to be 
the most clinically significant mechanism of carbapenem resistance 64. 
Carbapenemase enzymes were first identified in the 1980s and since then have successfully 
disseminated globally 15. Carbapenemase enzymes have a similar mode of action to other  
β-lactamases, and are considered to be the most powerful of the β-lactamases as they are 
able to hydrolyse most β-lactam antibiotics 63. There are a number of different types of 
carbapenemase enzymes and they can be divided into different classification groups based 
on their amino acid homology 65. The acquired carbapenemases can be grouped into the 
Ambler classes A, B and D 66. The different carbapenemases found so far include KPC, 
NDM, VIM, GES, SME, OXA-48, IMP, NMC, GIM, SPM, SIM, IMI, CMX and CcrA.  
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Morrill et al. stated that KPC, NDM, IMP, VIM and OXA-48 are the mostly commonly found 
carbapenemases in Enterobacteriaceae and are also those with the greatest clinical 
importance 7. The relatedness of these carbapenemase families has been demonstrated in 
the phylogenetic tree below (figure 1.4) and notable characteristics of these families have 
been laid out below in table 1.2. 
 
Figure 1.4: Phylogenetic tree demonstrating the relatedness of common carbapenemase genes. A, B 
and D refer to the Ambler classes. Adapted from Diene and Rolain (2014) 67. 
Table 1.2: Characteristics of common carbapenemase families. 
Carbapenemase 
family 
First discovered Class Hydrolysis profile 
KPC Northern America 
1996 
Ambler class A 
Serine β-lactamases 
Penicillins, carbapenems, all 
cephalosporins and 
aztreonam 
IMP Japan 1991 Ambler class B 
Metallo-β-lactamases 
All β-lactams except 
aztreonam 
VIM Italy 1997 Ambler class B 
Metallo-β-lactamases 
All β-lactams except 
aztreonam 
NDM India 2008 Ambler class B 
Metallo-β-lactamases 
All β-lactams except 
aztreonam 
OXA-48 Scotland 1993 Ambler class D 
Oxacillinases 
Penicillins, carbapenems and 
first generation 
cephalosporins 
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The spectrum of hydrolysis of β-lactam antibiotics depends on the specific carbapenemase 
enzyme 48,66. For example, aztreonam is hydrolysed by NMD, VIM and IMP, but not by KPC 
enzymes. KPC confers high-level resistance to carbapenems, whereas IMP and OXA-48 
carbapenemases may need efflux pumps or low outer membrane permeability additionally to 
achieve high-level carbapenem resistance 66. Carbapenem Resistant Enterobacteriaceae 
(CRE) are particularly concerning as they often carry additional resistance genes making 
them multi-resistant 68. The prevalence of these enzymes has increased significantly over 
the past decade, warranting increased concern 69.   
A review of carbapenemase resistance in South Africa reported that NDM and OXA-48 
carbapenemases are most commonly observed 64.  
KPC 
The first KPC carbapenemase, KPC-1, was isolated from a K. pneumoniae isolate in 
Northern America 48. The KPC enzymes belong to class A of the Ambler classification and 
are inhibited by clavulanic acid 66. They have the ability to hydrolyse penicillins, 
carbapenems, cephalosporins and aztreonam 48. KPC carbapenemases are powerful 
enzymes and do not need other resistance mechanisms to achieve high-level resistance 48. 
There are 11 variants (KPC-2 to KPC-12) of the first KPC enzyme, KPC-1 15.  
IMP 
IMP enzymes are grouped into class B of the Ambler classification, or the metallo-β-
lactamases of the Bush-Jacoby-Medeiros classification. They were the first acquired metallo-
β-lactamases, detected in Japan in 1991 15. Since then 33 variants have been identified 15. 
They have a broad substrate profile which includes all β-lactams with the exception of 
aztreonam 48. IMP carbapenemases are often found as part of gene cassettes situated 
inside integrons, along with other resistance genes 15.  
VIM 
VIM-1 was first reported in Verona, Italy in 1997. They are metallo or class B β-lactamases. 
They have a similar substrate profile to IMP enzymes, although they share little sequence 
similarity 48. Like IMP enzymes, they are also found on gene cassettes inside integrons 15. 
There are 33 known variants of this carbapenemase 15.  
NDM 
This type of metallo-β-lactamases was first discovered in 2008, isolated from a patient 
previously hospitalised in New Delhi, India 15. This emerging group of carbapenemases has 
since been identified worldwide and 13 variants have been described 70. These 
carbapenemases hydrolyse all β-lactams excluding aztreonam 70. Many NDM producing 
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strains have been found to express additional resistance mechanisms such as ESBLs, 
AmpC cephalosporinases and other carbapenemases 15.  
OXA-48 
OXA-48 carbapenemases are classified as oxacillinases or Ambler class D β-lactamases. 
OXA-48 enzymes hydrolyse penicillins and carbapenems, but not extended-spectrum 
cephalosporins. Isolates harbouring OXA-48 carbapenemases usually do not show high 
levels of resistance to carbapenems 15. This can make detection of these carbapenemases 
difficult in routine microbiology laboratories and may result in the underestimation of their 
prevalence 15.  
1.5.3 Epidemiology of β-lactam resistance in Enterobacteriaceae  
The distribution of resistant bacteria varies geographically, and differences may be due to 
patterns of antimicrobial use/misuse, healthcare practices, as well as environmental factors 
4. Understanding local epidemiology is important to guide empiric treatment, to understand 
potential transmission patterns, and to establish priorities for research and action. It can also 
assist in identifying risk factors and thereby strategies to prevent infection.  
The European Centre for Disease Prevention and Control (ECDC) compiled a report from 
the European Antimicrobial Resistance Surveillance Network (EARS-Net) which included 
antimicrobial resistance data from 30 European Union countries from 2012 to 2015 4. This 
report noted that resistance to third generation cephalosporins increased significantly in  
E. coli and K. pneumoniae and a large portion of these isolates produced an ESBL. For  
E. coli in 2015, the resistance to third generation cephalosporin’s ranged from 1.7% (Iceland) 
to 38.5% (Bulgaria), while the population weighted mean for all included countries was 
13.1%. For K. pneumoniae in 2015, the resistance ranged from 0% (Iceland) to 75.5% 
(Bulgaria), with a mean of 30.3%. Overall, both organisms showed an increase in resistance 
to third generation cephalosporins between 2012 and 2015; from 11.9 % to 13.1 % in E. coli 
and from 25.8 % to 30.3 % in K. pneumoniae 4. 
The rate of resistance to carbapenems observed in E. coli was quite low, with a population 
weighted mean of 0.1%. Many countries including Iceland, Belgium, Bulgaria, Finland, 
Lithuania and Slovakia saw no resistance to carbapenems in E. coli. Greece and Romania 
had the highest levels of carbapenem resistance in E. coli at 1.2% and 1.9% respectively. 
Carbapenem resistance in K. pneumoniae showed large variation between countries. Many 
countries reported resistance below 1% with a few countries, such as Iceland, Finland, 
Sweden and Lithuania reporting 0% resistance in 2015. The population weighted mean saw 
a significant increase from 6.2% in 2012 to 8.1% in 2015. Romania and Italy showed higher 
levels with 24.7% and 33.5% resistance respectively. Greece showed a concerningly high 
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level of resistance at 61.9%. It was also observed that generally countries with higher levels 
of resistance to a combination of third generation cephalosporins, aminoglycosides and 
fluoroquinolones also showed higher levels of carbapenem resistance. 
A non-systematic literature review looking at ESBL producing Enterobacteriaceae in Africa 
reviewed 65 studies published from 2008 to 2012 and found an ESBL prevalence of 1.3 to 
96% across Africa 71. This review included studies with various specimens. Some of the 
included studies were carried out in hospital settings only, with others in hospital and 
community settings. A summary of the prevalence of the ESBLs found in different African 
countries can be seen in the table below (table 1.3).  
Table 1.3: ESBL prevalence in African countries based on data from a review by Storberg (2014) 71. 
 Country ESBL prevalence (%) 
Northern Africa Algeria 16.4 – 31.4  
Egypt 11 – 42.9 
Guinea-Bissau 32.6 
Morocco 1.3 – 7.5 
Libya 16 
Tunisia 11.7 – 77.8 
Eastern Africa Ethiopia 62.8 
Kenya 37.4 
Rwanda 5.9 – 38.3 
Central Africa Cameroon 17.2 – 82.8 
Central African Republic 11.3 
Western Africa Ghana 49.4 
Mali 63.4 – 96 
Niger 40 
Nigeria 10.3 – 27.5 
Senegal 10 
Southern Africa South Africa 8.8 – 13.1 
 
A meta-analysis of the available literature about the prevalence of ESBLs in 
Enterobacteriaceae in East Africa found rates of between 30.9-61.7%, with an average of 
42% 11. More specifically, the ESBL proportion estimate for the specific countries were 
Tanzania 38.8%, Kenya 45.8%, Ethiopia 30.9%, Uganda 61.7%, and Rwanda 38.3%.  
A study in Ghana collected Enterobacteriaceae isolates from various sites in 2008 72. 
Overall, they found an ESBL prevalence of 49.3%. In K. pneumoniae and E. coli specifically, 
the prevalence was 61.5% and 43% respectively.  
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A study conducted in Morocco in 2013 examined the prevalence of ESBLs and 
carbapenemasas from rectal swabs 73. The prevalence of ESBL producing 
Enterobacteriaceae was found to be 42.8%; for E. coli and K. pneumoniae the prevalence 
was 48.5% and 39.4% respectively. The prevalence of carbapenemases was 12.8%, all of 
which were OXA-48 carbapenemases.  
A similar study examining the prevalence of ESBLs in Enterobacteriaceae from rectal swabs 
of children in Gabon, found an overall carriage rate of 45% 74. Interestingly, this carriage rate 
increased with length of stay before the rectal swab was collected. When sampling at 48 
hours after admission, the prevalence was 33.6%, this increased to 46.5% by 3-4 days, 
66.6% by 5-6 days and 94.1% when swabbed 7 or more days after admission. This indicates 
possible nosocomial transmission of ESBL producing Enterobacteriaceae 74.  
A report in 2011 that looked at BSIs at public sector hospitals across South Africa, found that 
3-17% of E. coli isolates and 55-74% of K. pneumoniae isolates were ESBL producers. 
However the majority of these isolates (96-100%) were susceptible to carbapenems 6. The 
specific data on ESBL production is not reported reliably, and therefore ESBL production is 
often inferred from cephalosporin resistance. This study also looked at rates of resistance in 
Tygerberg Hospital and found that 11% of E. coli isolates were ESBL producers (vs 16% 
average for all sites included in the study) and all E. coli were susceptible to carbapenems 6. 
The prevalence of ESBLs was much higher in K. pneumoniae at 56%, and similarly, all 
isolates were susceptible to carbapenems.  
The National Institute for Communicable Diseases (NICD) and Corporate Data Warehouse 
(CDW) at the National Health Laboratory Service (NHLS) compiled a report which examined 
antimicrobial resistance trends in South African hospitals 5. The data was obtained from 
results generated by public health laboratories across South Africa for the year of 2015. The 
report stated that it did not see a significant increase in the resistance to the β-lactam group 
of antibiotics (including third generation cephalosporins and carbapenems) for E. coli from 
2014 to 2015. Resistance to third generation cephalosporins was assumed indicative of 
ESBL production and was found to be 22% overall for E. coli. Levels of carbapenem 
resistance in E. coli remained low, ranging from 0% to 4%, with the majority of sites reporting 
a 0% resistance rate. Overall, antimicrobial resistance in K. pneumoniae was much higher, 
with resistance to third generation cephalosporins at 69%. The resistance rates to the 
carbapenem, ertapenem, remained unchanged from the previous year at 4%, while for 
meropenem and imipenem it increased from 3% to 6%. The majority of carbapenem 
resistant isolates (for all bacterial species) were submitted to the NICD to confirm the 
presence of carbapenemases and identify the type of carbapenemase. The majority (63%) 
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of the isolates were K. pneumoniae and the most common carbapenemase gene isolated 
was NDM (50%) followed by OXA-48 (27%).  
A meta-analysis study examining the ESBL epidemiology in Enterobacteriaceae in East 
Africa, found CTX-M ESBL genes to be the most common (45.4-88.5%) followed by TEM 
(16-55%) and then SHV (3-64%) 11. 
An investigation into the carriage of ESBLs in Enterobacteriaceae from rectal swabs of 
children in Gabon, found CTX-M to be the most commonly found ESBL 74. The specific 
prevalence of genes found in K. pneumoniae was 89.6% CTX-M, 70.1% SHV and 85.1% 
TEM. For E. coli, the prevalence was 86.7% CTX-M, 6.7% SHV and 56.7% TEM. The most 
commonly found CTX-M was CTX-M-15.  
A study carried out in South Africa in 2004 looked at ESBL genes present in K. pneumoniae 
isolates identified as ESBL producers by phenotypic testing 75. This study gathered isolates 
from various sites across South Africa. SHV and TEM β-lactamases and ESBLs were the 
most common ESBLs, which were most commonly found together (66% of the isolates). 
Unfortunately, they did not distinguish between β-lactamase and ESBL TEM and SHV 
genes. Interestingly, no CTX-M enzymes were found in the isolates. This is different to other 
studies conducted which report CTX-M as the most common ESBL.  
A study conducted in the Eastern Cape of South Africa from 2011- 2014 looked at ESBL 
production and screened for ESBL genes 76. This study focussed on Klebsiella species, and 
found that 69% of K. pneumoniae isolates phenotypically presented as ESBL producers by 
disc diffusion. When examining the prevalence of ESBL genes in these isolates, they found 
most common profile was TEM, SHV and CTX-M (56%) followed by SHV alone (16%). No 
isolates contained carbapenemase genes, although only NDM and KPC genes were 
screened for.  The study calculated the prevalence of TEM, SHV and CTX-M genes alone or 
in combination over the study duration, the total prevalence of TEM genes was 67%, SHV 
was 77% and CTX-M was 57%.  
Comparison of results from different studies is challenging as reporting systems differ as well 
as study design. Variation may be seen as a result of the methods used to estimate 
resistance. Some studies report on phenotypic methods while other use molecular methods 
or a combination of both 11. Site of infection and type of specimen may also play a role in the 
estimates of ESBL prevalence. It has also been said that stools tend to show a higher 
prevalence of ESBLs 71. The setting of the study may also influence the estimates, and in 
hospital settings the particular ward may also influence the prevalence of ESBLs 11. 
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1.5.4 Molecular epidemiology of antibiotic resistance in E. coli and K. pneumoniae 
Many studies have investigated the relationship between resistance genes and certain 
strains of E. coli and K. pneumoniae, known as Sequence Types (STs). STs have identical 
allelic profiles and may be considered bacterial clones. Specific clones carrying resistance 
genes have spread globally, these clones are considered to be highly successful or high-risk 
clones 51. Certain STs of E. coli and K. pneumoniae commonly harbour specific resistance 
genes or combinations of resistance genes 77. It has been suggested that resistance 
plasmids are essential in the rapid spread of high-risk clones and that these clones harbour 
resistance genes and therefore play a major role in the spread of these genes 51,77. The 
resistance genes are spread vertically from generation to generation by the bacterium and 
can also be transferred horizontally to other bacteria 77.  
Certain STs of E. coli , such as ST648, ST617, ST167, ST410, ST224, and ST117, have 
been linked to ESBL production 78. Most notably E. coli ST131 has been linked to the 
worldwide dissemination of the CTX-M-15 gene 77,78. This clone is known to carry additional 
resistance determinants and is therefore multi-drug resistant 51. Studies have shown the 
increasing prevalence of this clone, not only in clinical settings but also in the community 78. 
K. pneumoniae STs have also been linked to carriage of specific resistance genes, such as 
the association between ST258 and the carbapenemase KPC 77. Studies have also found 
certain β-lactamase genes to be associated with one another as well as with other 
resistance genes, such as CTX-M-15, TEM-1, OXA-1 and the aminoglycoside modifying 
enzyme aac(6’)-Ib-cr 79.  
In some countries, resistant isolates mostly belong to these successful clones, while in 
others the resistant isolates are more diverse 77. For example, in some countries the E. coli 
population is dominated by the clone ST131, while in other countries several clones are 
found 77. It has been highlighted that even specific widespread clones may harbour different 
resistance genes based on their environment 77. While there are trends in clonal lineages 
and the resistance genes they harbour, each country may have its own frequency of clones 
and resistance. This highlights the epidemiological importance of investigating the sequence 
type and genes conferring drug resistance in local populations. 
Various strain typing techniques can be used to elucidate the population structure and clonal 
relatedness of circulating strains and may also assist in identifying the source of infections, 
which may be particularly helpful during an outbreak 80. Strain typing of isolates in a 
particular setting is also helpful for surveillance as well as evaluating the efficacy of the local 
Infection Prevention and Control (IPC) strategies 81. There are a number methods available, 
with molecular methods taking the forefront, due to their higher discrimination and ability to 
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type unculturable bacteria 81. Frequently used molecular typing techniques make use of 
DNA-based methods that investigate chromosomal or plasmid DNA using probes, restriction 
enzymes, Polymerase Chain Amplification (PCR) and sequencing 81. Some commonly used 
strain typing techniques include rep-PCR, Pulsed Field Gel Electrophoresis (PFGE), 
Multilocus Sequence Typing (MLST) and Variable Number Tandem Repeat (VNTR) 
analysis. The development of newer technologies such as microarrays and Whole Genome 
Sequencing (WGS) has greatly enhanced strain typing. Each strain typing method has 
different performance variables, such as discrimination, throughput, cost, speed and 
availability, which are considered before implementing a technique 81. Often a combination of 
techniques is used to increase reliability of results.  
1.6 Conclusion 
Therapeutic decisions need to be made based on local epidemiology. Surveillance systems 
need to be established in order to determine the burden of infections with resistant bacteria, 
the specific risk factors for their acquisition and the outcome of infection with these bacteria 
11. This type of data from other settings may not be transferable to more resource limited 
African settings; therefore, surveillance studies need to be undertaken.  
Action needs to be taken to ensure antibiotics are used as effectively and sparingly as 
possible. A balance must be found between curing infections now and conserving antibiotics 
so that they may also be effective for future use. It is important to make sure patients are 
receiving optimal doses of antibiotics and that antibiotic treatment is de-escalated to 
narrower spectrum agents or monotherapy after receiving species identification and 
antibiotic susceptibility results from the laboratory.  
There is a great need to acquire as much information as possible about the epidemiology in 
our local area as well as the specific risk factors associated with these infections and place 
great importance on the value of infection prevention and control, so that we can prevent 
these infections as far as possible, treat them as effectively as possible and prevent their 
spread.  
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Aim and objectives 
The aim of this study was to describe the epidemiology of E. coli and K. pneumoniae strains 
isolated from blood cultures at Tygerberg Hospital over the period of one year.  
Objectives: 
1. Detect and identify ESBL genes in the isolates using a PCR assay 
2. Detection and identification of carbapenemase genes by PCR 
3. Perform strain typing on collected isolates using rep-PCR and PFGE 
4. Determine whether there is a link between strain type and resistance mechanisms 
5. Differentiate community-acquired and healthcare-acquired infections and investigate 
the shared features among these groups. 
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Chapter 2: Prevalence and susceptibility of 
collected isolates 
1. Introduction 
Bloodstream infection (BSI), or bacteraemia, is defined as the presence of viable bacteria in 
the blood 23,24. It is a notable cause of morbidity and mortality, and has fatality rates ranging 
from 10 to  70% 17,23,25,26. BSIs can be categorised by where they were acquired, causative 
microorganism and focus of infection 82.  
One method of classifying BSIs is based on where the infection was contracted, namely 
community- or hospital-acquired 28. Community-acquired infections are those which were 
present or incubating at the time of admission to hospital, while hospital-acquired infections 
are those which occur after admission to the hospital, typically defined as acquisition 48 
hours or more after admission 82. These different types of BSIs can differ in epidemiology, 
severity and mortality, and importantly may influence the choice of empiric therapy 17,23. 
BSIs may also be classified by the type of microorganism, and the microorganism/s causing 
infection may differ between settings 82. Recently Gram negative bacteria, and the 
Enterobacteriaceae in particular, have re-emerged as a predominant cause of BSIs 28. 
Escherichia coli and Klebsiella pneumoniae are two organisms implicated as major causes 
of BSIs 33. Studies conducted in South Africa have found E. coli and K. pneumoniae to be 
the most common causes of Gram negative bacteraemia 17,32.  
Bacteraemia may arise as a primary infection, or secondary to an infection at a defined 
anatomical site. The focus of infection may also be used to classify bacteraemia. Common 
foci of BSIs include urinary tract infections and lower respiratory tract infections 82. Hospital-
acquired BSIs are commonly associated with central venous catheters 82.   
Identification of the causative organism is essential for effective treatment of BSIs, and is 
usually done by blood culture. Blood from the affected patient is cultured and the cultured 
organism is identified and tested for antibiotic susceptibility. These tests take 24 to 72 hours 
to obtain results; therefore empiric treatment is frequently relied on until more information is 
available. In some resource limited settings where there is little or no access to diagnostic 
facilities, empiric treatment is often relied on alone 36.  
Correct and timely treatment has been found to reduce mortality from serious bacterial 
infections 83 . However, increasing rates of antibiotic resistance in bacteria has made the 
Stellenbosch University  https://scholar.sun.ac.za
22 
 
empiric selection of appropriate agents increasingly challenging, and thus detrimental to 
patients 37. This highlights the need for recent information about the epidemiology of 
circulating pathogens as well as their resistance rates. Studies have shown that improper 
empiric treatment results in increased morbidity and mortality, especially when these 
bacteria contain resistance mechanisms such as Extended Spectrum β-lactamases (ESBLs) 
and carbapenemases 38. 
Surveillance of BSIs will help to estimate the burden of these infections, predict outcome and 
identify potential risk factors. The aim of this chapter was to investigate the antibiotic 
resistance and mortality rate of Gram negative BSIs in our setting and to differentiate 
between community-acquired and healthcare-acquired infections.  
2. Materials and Methods 
2.1 Sample selection 
Isolates of E. coli and K. pneumoniae were obtained from positive blood cultures at the 
National Health Laboratory Service (NHLS) microbiology diagnostic laboratory in Tygerberg 
Hospital over 12 months, from April 2015 to March 2016. Only isolates from patients being 
treated at Tygerberg Hospital were included and isolates were convenience samples. These 
included blood cultures from adult and paediatric patients. The blood cultures were taken as 
part of regular patient investigation. All collected isolates were processed and identified 
using the laboratory’s standard operating procedures. Isolate information was obtained from 
the Laboratory Information System (LIS) and stored in a secure database.  
2.2 Sample processing 
Blood culture bottles were incubated using the BacT/ALERT instrument (bioMérieux, 
France). Once a bottle was identified by the machine as positive, the bottle was removed 
from the machine and processed. Processing entails Gram staining, followed by culturing the 
organism to identify the species and generate the organism’s antibiogram. Isolates were 
cultured using Tryptone Bile agar (TBA), MacConkey agar (MCC) and Chocolate agar 
(CHOC) and incubated overnight. This culture was then used to identify isolates using the 
VITEK®2 Advanced Expert SystemTM (bioMérieux, France) as per manufacturer’s 
specifications. Antibiotic susceptibility testing was performed directly from the blood culture 
bottle by disc diffusion testing using the Kirby-Bauer method, using Mueller Hinton (MH) agar 
plates and antibiotic susceptibility discs (Mast Diagnostics, United Kingdom and Oxoid 
Limited, United States of America). Antibiotic susceptibility results were interpreted using the 
Clinical and Laboratory Standards Institute (CLSI) guidelines (2016). If the isolates showed a 
highly resistant profile, were suspected ESBL producers or had inconsistent results, 
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antibiotic susceptibility profiles were confirmed using the VITEK®2 Advanced Expert 
SystemTM as per manufacturer’s instructions. Resistance to the cephalosporin cefotaxime, 
was used as a marker for ESBL production. 
The selected isolates were cultured on TBA to obtain pure colonies and then stored using 
MicroBank™ (Pro-Lab Diagnostic, United Kingdom) beads. This was done by taking a loop 
full of culture from the agar plates and inoculating the cryopreservative in the tube. The tube 
was then inverted 10 times and allowed to incubate on the bench for at least 2 minutes. 
Thereafter, the cryopreservative was removed using a pipette. The tube of beads was then 
stored in a labelled box at -80°C.  
2.3 Patient information and statistical analysis 
Specific patient information was obtained from the Hospital Information System (HIS), 
CLINICOM, and the LISs Disalab and TrakCare. This information included age, gender, 
ward, date of admission, duration of hospital stay and outcome. 
BSIs were categorised as community-acquired or hospital-acquired based on where the 
infection was contracted. If the infection was present at admission or within 72 hours it was 
classified as community-acquired; if it was only observed after 72 hours in hospital it was 
classified as hospital-acquired. However, if the patient was previously hospitalised for two or 
more days within the past 90 days, the infection was classified as hospital-acquired 84. A 72 
hour cut off was opted for instead of a 48 hour cut off as only date of admission was 
available not the specific time, therefore this cut off would give a better indication of 
community- or hospital-acquired infections.  
Statistical analysis was performed with the assistance of the Biostatistics unit from the 
Centre for Evidence-based Health Care at Stellenbosch University. IBM SPSS statistics 
version 25 was used for all statistical analysis. The chi-square test was used to estimate the 
significance of the correlation with statistical significance defined as <0.05.  
Ethical approval for this study was obtained from the Human Research Ethics Committee 
(HREC) of Stellenbosch University (HREC# N14/06/069).  
3. Results 
3.1 Sample selection 
One hundred and forty isolates (70 E. coli and 70 K. pneumoniae) were collected from April 
2015 to March 2016. A total of 257 blood cultures cultured E. coli (n=142) and  
K. pneumoniae (n=115) over this period, therefore 54.4% of blood cultures were collected.  
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3.2 Patient demographics 
Approximately one third of the patients (43/140; 30.7%) were paediatric, i.e. 15 years or 
younger 85, and two thirds were adult patients (97/140; 63.3%). The youngest patient was 
four days old while the oldest was 84 years old. Twenty-five (58.1%) of the paediatric 
patients were less than 12 months old.  Forty-three (44.3%) adult patients were over 50 
years, and 15 (15.5%) were 65 years or older. Sixty-three (45%) of patients were male, 76 
(54%) were female and one patient was intersex. These patients were situated in various 
wards throughout Tygerberg Hospital (Table 2.1).  
Table 2.1: Distribution of patients at Tygerberg Hospital. 
Ward Number of patients 
Adult emergency 29 20.7% 
Adult surgery 26 18.6% 
Paediatric medical 25 17.9% 
Adult medical 17 12.1% 
Obstetrics 12 8.6% 
Adult ICU 10 7.1% 
Paediatric ICU 7 5% 
Paediatric surgery 6 4.3% 
Paediatric emergency 6 4.3% 
Out patient 2 1.4% 
 
Ninety-three (66.4%) of the BSIs were hospital-acquired, while 47 (33.6%) were community-
acquired (table 2.2). Of the hospital-acquired isolates, 57 (61.3%) were K. pneumoniae and 
36 (38.7%) were E. coli. Of the community-acquired isolates, 13 (27.7%) were  
K. pneumoniae and 34 (72.3%) were E. coli. The distribution of E. coli and K. pneumoniae 
isolates in community- and hospital-acquired infections was statistically significant 
(p<0.0001).  
Table 2.2: Distribution of hospital- and community-acquired isolates. 
Type of BSI Organism  Total 
Hospital-acquired 57 K. pneumoniae (61.3%) 93 (66.4%) 
36 E. coli (38.7%) 
Community-acquired 13 K. pneumoniae (27.7%) 47 (33.6%) 
34 E. coli (72.3%) 
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The duration of hospitalisation before and after the blood culture was taken was recorded. 
Patients spent an average of 11 days in hospital before the blood culture was taken, ranging 
from 0 to 133 days, with a median of 4.5 days. Patients spent on average 18 days in hospital 
after their blood culture was taken, with a median of 12 days. The number of days spent in 
hospital after the blood culture was taken ranged from 0 to 105 days. 
The 30-day outcome for all patients is shown in figure 2.1. The crude 30-day mortality rate 
was 30% (42/140), although exact cause of death is not known. The crude mortality rate for 
the paediatric patients (32.6%; 14/43) was slightly higher than for adult patients (28.9%; 
28/97) but this was not statistically significant. The mortality rate for E. coli and  
K. pneumoniae BSIs was similar, at 28.6% (20/70) and 31.4% (22/70) respectively. 
 
Figure 2.1: 30-day outcome of patients. 
The crude mortality for hospital-acquired BSIs was 33.7% (31/92), while it was lower in 
community-acquired infections at 22.9% (11/48). This was also not statistically significant 
(p=0.183).  
3.3 Phenotypic resistance 
The antibiotic susceptibilities of the isolates can be seen in figure 2.2. K. pneumoniae 
isolates showed more resistance than E. coli to all antibiotics, except for co-trimoxazole, to 
which E. coli isolates were slightly more resistant. Little resistance to amikacin and 
ertapenem was seen in the isolates.  
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Figure 2.2: Antibiotic resistance results of all isolates. 
Fifty isolates tested resistant to cefotaxime and were classified phenotypic ESBL producers. 
The resistance profile of ESBL producers compared to non-ESBL producers can be seen in 
figure 2.3. Increased resistance was seen in ESBL producers, particularly to co-trimoxazole, 
ampicillin, co-amoxclav, ciprofloxacin, gentamicin and piperacillin-tazobactam. 
 
Figure 2.3: Comparison of antibiotic resistance of ESBL producers versus non-ESBL producers.  
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The resistance profiles of isolates classified as hospital- or community-acquired can be seen 
below (table 2.3). Phenotypic ESBL production in hospital-acquired isolates was higher at 
46.2% (43/93), compared to community-acquired isolates at 14.9% (7/47). The association 
between hospital-acquired isolates and phenotypic ESBL production was statistically 
significant (p<0.0001). 
Table 2.3: Antibiotic susceptibility results (sensitivity), shown as percentage of total number of 
isolates. 
 E. coli (n=70) K. pneumoniae (n=70) Total (n=140) 
 Antibiotic HA 
(n=36) 
CA 
(n=34) 
HA 
(n=57) 
CA  
(n=13) 
HA 
(n=93) 
CA 
(n=47) 
Co-trimoxazole 25.0 44.1 26.3 76.9 25.8 53.1 
Ampicillin 11.1 35.3 0.0 0.0 4.3 25.5 
Co-amoxiclav 58.3 79.4 38.6 69.2 46.2 76.6 
Ciprofloxacin 75.0 76.5 61.4 92.3 66.7 80.9 
Cefotaxime 80.6 88.2 36.8 76.9 53.8 85.1 
Gentamicin 88.9 79.4 43.9 76.9 61.3 78.7 
Amikacin 97.2 100.0 93.0 100.0 94.6 100.0 
Piperacillin-tazobactam 80.6 97.1 71.2 92.3 74.2 95.7 
Ertapenem 100.0 100.0 98.3 100.0 98.9 100.0 
4. Discussion 
4.1 Patient demographics 
Fifty-four percent of E. coli and K. pneumoniae isolates from blood cultures were collected. 
Although, not all E. coli and K. pneumoniae isolated over the one year time period were 
included due to isolates being collected by convenience, the collection of isolates is believed 
to be representative of the total population. A third of patients included in the study were 
paediatric, with 56.8% (25/44) of these patients being less than 12 months old. BSIs are 
known to affect patients at the two extremes of life 24, however not many patients of 
advanced age were seen in this study. Patients whose blood cultures were included in this 
study were located in various wards across Tygerberg hospital.  
Two thirds of the isolates were classified as hospital-acquired. This may be influenced by the 
fact that Tygerberg is a tertiary hospital and patients are referred from other healthcare 
facilities, and usually have more complex pathology. Nonetheless, this provides an 
opportunity to reduce these infections through preventative measures, such as improved 
hand hygiene and removing intravenous lines as soon as possible 17.  
Hospital-acquired isolates were predominantly K. pneumoniae (61.3%; 93/140), while 
community-acquired isolates were mostly E. coli (72.3%; 47/140).  A study conducted at 
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another hospital in Cape Town, which investigated community- versus healthcare-acquired 
BSIs, also observed that more K. pneumoniae isolates were healthcare-acquired than 
community-acquired (15.8% vs 7.1%), and more E. coli isolates were community-acquired 
than healthcare-acquired (19.8% vs 9.9%) 17. Likewise, a Tanzanian study on BSIs in 
children (0-7 years) observed more K. pneumoniae isolates to be healthcare-acquired than 
community-acquired (24.5% vs 12.3%), and more E. coli isolates to be community-acquired 
than healthcare-acquired (15.5% vs 9.4%) 34. K. pneumoniae is a known nosocomial 
opportunistic pathogen that is often found in hospital settings and has notable ability to 
survive on hands, facilitating its spread 19.  
Patients spent an average of 11 days in hospital before the blood culture was taken, and an 
average of 18 days after it was taken. It has been found that BSIs increase hospital stays by 
10 days 86. A lengthier hospital stay increases a patient’s risk for subsequent infection, due 
to underlying morbidity and invasive procedures 87. Unfortunately, this study did not include a 
control group to better define the additional length of stay for patients with BSI.  
The 30-day mortality rate of 30% (42/140) is a crude estimate as the exact cause of death 
was not ascertained. However, 30-day crude mortality is a common outcome in similar 
studies and at least allows for some comparisons. The mortality in this study was higher than 
another study conducted in Tygerberg Hospital from 2008 to 2013, 20.4%,  and studies 
conducted in the United States of America, 11.5-16%, Canada, 14-22.5%, Denmark, 12-16% 
and Spain 19-24% 27,32,82,88. This may be because these studies included BSIs caused by 
Gram positive and negative bacteria and fungi.  Studies have noted a lower mortality in 
Gram positive BSIs than Gram negative BSIs 32,34,35. Aiken et al. found fungal infections to 
have a higher mortality than Gram positive BSIs, but still much lower than Gram negative 
BSIs, in contrast, Dramowski et al. found fungal bacteraemia to be associated with mortality. 
The mortality in this study was lower than reported in a Tanzanian study, 43.5%, and a 
Kenyan study, 61% 34,35. Both studies focussed on paediatric patients and included patients 
with other severe co-morbidities such as HIV-infection and malnutrition. The Kenyan study 
only included hospital-acquired infections, which may explain why the mortality rate is 
higher. Blomberg et al. noted that expensive second-line antibiotics are not readily available 
in Tanzania.  
The mortality rate was higher in hospital-acquired isolates (33.7%; 31/92) than community-
acquired (22.9%; 11/48) isolates, although this was not statistically significant. Other studies 
have also found increased mortality in hospital-acquired infections as opposed to 
community-acquired 32,35,88,89. A study conducted in Kenya reported an alarming mortality 
rate of 53% in hospital-associated BSIs versus 24% in community-acquired infections 35. 
Hospital-acquired infections have an increased mortality rate as hospitalised patients often 
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have co-morbidities such as HIV-infection, cancer and tuberculosis, and may be 
immunocompromised due to the treatment they are receiving. Hospital-acquired bacteria are 
also often antibiotic resistant thereby complicating and delaying effective treatment.  
4.2 Phenotypic resistance 
High levels of resistance were seen to co-trimoxazole (65%; 91/140) and ampicillin (88.6%; 
124/140). Most isolates remained sensitive to amikacin (96.4%; 135/140) and ertapenem 
(99.3%; 139/140), and piperacillin-tazobactam also retained a reasonable level of 
susceptibility (81.4%; 114/140).  
Susceptibility data was only recorded as categorical and not Minimal Inhibitory 
Concentrations (MIC), as not all isolates were tested on the VITEK®2. This places limitations 
on the analysis of the data. Additionally, if an isolate is a suspected ESBL producer, all 
cephalosporins are recorded non-susceptible. A similar problem exists with co-amoxiclav, 
piperacillin-tazobactam, gentamicin and amikacin, which may be reported as non-
susceptible by the VITEK®2 if an underlying resistance mechanism is detected.  
Resistance to the third generation cephalosporin, cefotaxime, was used as a marker for 
phenotypic ESBL production. Fifty isolates (35.7%) were ESBL producers, 78% (39/50) of 
these were K. pneumoniae isolates and 22% (11/50) were E. coli isolates. This translates to 
55.7% of K. pneumoniae isolates and 15.7% of E. coli isolates being ESBL producers. A 
study conducted in a hospital in Cape Town in 2012 found similar rates of ESBL production 
in blood culture isolates, 30%, although this was for all Enterobacteriaceae isolates 17. A 
study done on BSIs at Tygerberg Hospital reported similar rates of ESBL production in  
E. coli (12-22%), but much higher rates in K. pneumoniae (76-78%) 32. This may be as a 
result of only paediatric patients being included in the study. 
A report on BSIs at public sector hospitals across South Africa in 2011, found that 3-17% of 
E. coli isolates and 55-74% of K. pneumoniae isolates were ESBL producers 6. At Tygerberg 
Hospital, they reported 16% of E. coli isolates and 56% of K. pneumoniae isolates to be 
ESBL producers, which is akin to what our study found. A report looking at resistance in 
public hospitals across South Africa in 2015 reported a higher rate of resistance to third 
generation cephalosporins, at 22% for E. coli and 69% of K. pneumoniae 5. The resistance 
rates they reported at Tygerberg Hospital were similar to what was found in our study, 13% 
for E. coli and 54% of K. pneumoniae. This report included all specimen types in the 
resistance rates. The European Centre for Disease Prevention and Control (ECDC) reported 
the average resistance to third generation cephalosporins for European Union (EU) 
countries; and found a similar resistance rate of 13% for E. coli, while for K. pneumoniae the 
resistance was much lower than found in this study at 30% 4.  
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The resistance profile of the subset of isolates classified as ESBL producers was determined 
and compared to non-ESBL producers (figure 2.3). An increase in resistance was seen to 
most antibiotics, i.e. co-trimoxazole, ampicillin, co-amoxiclav, ciprofloxacin, gentamicin and 
piperacillin-tazobactam. ESBL genes are often harboured on large plasmids that contain 
other resistance genes, resulting in resistance to other antibiotics such as aminoglycosides, 
tetracyclines, chloramphenicol and sulphonamides 90. ESBL producing bacteria are also 
known to be more resistant to fluoroquinolones 90. Studies conducted across Europe from 
2004-2007 found ESBL production to be associated with resistance to other antibiotics such 
as to co-trimoxazole, tetracycline, gentamicin, and ciprofloxacin 60. ESBL producers retained 
their sensitivity to amikacin and ertapenem. This is beneficial as these antibiotics are often 
used to treat ESBL producing organisms 17.  
Resistance was compared between the hospital- and community-acquired isolates. 
Increased resistance was seen to most antibiotics in the hospital-acquired isolates, although 
most isolates remained sensitive to amikacin (94.6%; 88/93) and ertapenem (98.9%; 92/93). 
ESBL prevalence was much higher in hospital-acquired isolates (46.2%; 43/93), compared 
to community-acquired isolates (14.9%; 7/47). Increased resistance in hospital-acquired 
isolates is expected, as increased use of antibiotics in hospital settings places considerable 
selection pressure on circulating bacteria 17.   
Although community-acquired isolates were more susceptible to antibiotics than hospital-
acquired isolates, reduced susceptibility was still observed in these isolates. Resistance was 
observed to co-trimoxazole (46.8%; 22/47), ampicillin (74.5%; 35/47), co-amoxiclav  
(23.4%; 4/47), gentamicin (21.3%; 10/47), ciprofloxacin (15.2%; 9/47) and cefotaxime 
(14.9%; 7/47). Little resistance was seen to piperacillin-tazobactam (4.3%; 2/47) and no 
resistance was seen against amikacin or ertapenem. These resistance rates are lower than 
what was reported in a study in Cape Town looking at community- versus healthcare-
acquired BSIs 17. A study on paediatric BSIs in Tanzania recorded higher rates of resistance 
in community-associated E. coli and K. pneumoniae isolates, except for ciprofloxacin which 
had low levels of resistance (0-8%) 34. Dramowski et al. noted a concerningly high level of 
antibiotic resistance in community-acquired E. coli and K. pneumoniae isolates from 
Tygerberg, although specific values were not given 32. Antibiotic resistance in community-
acquired bacteria may be due to previous antibiotic use or prior time spent in healthcare 
facilities. Previous antibiotic use is a known risk factor for resistance 91. 
A review looking at the prevalence of ESBLs in BSIs in Africa found that African countries 
have a lower prevalence of ESBLs in community settings as compared to hospital settings 
92. African countries reported varying rates of resistance, with most reporting an increase in 
ESBL prevalence in hospital settings. Tunisia recorded community setting prevalence of 0.7-
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7.3% and hospital setting prevalence of 11.7-77.8%, across five studies. Kenya and Ethiopia 
reported a prevalence of 11% in community settings and 42.9% in hospital settings. The 
review also recorded an ESBL prevalence of 0.3-4.7% for community-acquired isolates and 
8.8-13.1% for hospital-acquired isolates in South Africa. This is much lower than what was 
observed in this study. This may be due to the fact that these studies were carried out from 
2002 to 2009 and prevalence has since increased. A study which focused on BSIs at a 
hospital in Cape Town in 2011 reported a similar rate of ESBL producers in hospital-
acquired Enterobacteriaceae isolates, 39.6%, but a much lower rate in community-acquired 
isolates, 5% 17.  
Within the hospital-acquired isolates, reduced susceptibility to all antibiotics was observed 
for K. pneumoniae compared to E. coli (table 2.3). A considerable reduction in sensitivity 
was observed for cefotaxime (ESBL production) and gentamicin in K. pneumoniae, 36.8% 
and 43.9% respectively, in comparison to E. coli, 80.6% and 88.9%. Similar differences in 
ESBL production between hospital-acquired E. coli and K. pneumoniae BSIs were reported 
in a previous study carried out in Tygerberg Hospital 32. They reported an ESBL production 
of 75.7% in K. pneumoniae and 21.7% in E. coli.  
5. Conclusion 
Two-thirds of isolates included in this study were hospital-acquired. Hospital-acquired BSIs 
were mostly caused by K. pneumoniae, while community-acquired infections were mostly 
caused by E. coli.  
A crude mortality rate of 30% was reported for this study, which is higher than reported in 
other studies in Africa and Europe. A higher mortality was reported for hospital-acquired 
infections, although this was not significant. The reported mortality figures are crude; 
however it would be advantageous to gain further clinical information into cause of death to 
determine whether mortality is a direct cause of the BSI or as a result of other comorbidities. 
Additional clinical information may also assist to identify further risk factors for infection and 
mortality. A prospective study is underway to collect such data. 
Isolates resistant to the third generation cephalosporin, cefotaxime, were presumed ESBL 
producers.  Fifty isolates (35.7%) were ESBL producers, mostly made up of K. pneumoniae 
isolates. Increased antibiotic resistance was observed among these isolates, which may be 
as a result of multiple resistance genes being present on a single plasmid.  
Increased resistance was observed among hospital-acquired isolates which was expected 
due to the increased selection pressure in hospital settings. Hospital-acquired  
K. pneumoniae isolates showed notably increased resistance, particularly to cefotaxime and 
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gentamicin. Fortunately, ertapenem and amikacin retained effectivity, and these antibiotics 
are often used as empiric therapy for hospital acquired infections.  
The information generated is important to guide empirical treatment as there are 
epidemiological differences in hospital- and community-acquired isolates. Incorrect empiric 
therapy has been associated with increased mortality, particularly with ESBL producing 
bacterial infections 38,83. 
It would be beneficial to collect additional information about previous antibiotic use to 
determine whether specific treatment is a risk factor for infection with ESBL producing 
organisms. Identification of risk factors may assist to prevent infections and focus 
preventative measures. Studies have found that using carbapenems for the treatment of 
infections with ESBL producing bacteria has resulted in lower mortality, although it is 
important to maintain the effectivity of carbapenems through antibiotic stewardship 32. 
Thorough resistance information will assist in determining which antibiotics are viable for 
treatment in this setting, so that we may preserve agents such as carbapenems and colistin. 
 
Stellenbosch University  https://scholar.sun.ac.za
33 
 
Chapter 3: Strain typing 
1. Introduction 
Strain typing is used to elucidate the relationships between microorganisms. Understanding 
this relatedness is important to identify the local epidemiology, but also to determine routes 
of transmission, sources of outbreaks, identify virulent strains and evaluate infection control 
measures 81.  
There are several strain typing methods available, with molecular methods becoming 
increasingly prominent as a result of their higher discriminatory ability 81. Some methods, 
such as Pulsed Field Gel Electrophoresis (PFGE) and Restriction Fragment Length 
Polymorphism (RFLP) analysis involve analysing chromosomal DNA with restriction 
enzymes. Others are amplification based like rep-PCR and Variable Number Tandem 
Repeat (VNTR) analysis or sequence based such as Multilocus Sequence Typing (MLST), 
microarrays and Whole Genome Sequencing (WGS) 81. 
The choice of which strain typing method to use is dependent on performance variables and 
the epidemiological question to be answered 81. Some performance variables to consider 
include repeatability, reproducibility, discriminatory power, throughput, ease of interpretation, 
time and cost. Two strain typing techniques are often combined to enhance or strengthen 
results. Typing technologies based on the whole genome of the microorganism yield better 
results in establishing the clonal relationships 93.  
Rep-PCR entails the Polymerase Chain Reaction (PCR) amplification of repetitive extragenic 
palindromic (REP) elements which are highly conserved and dispersed throughout the 
bacterial genome 94. It has been proposed that these elements are involved in mRNA 
stability, termination of transcription and chromosomal domain organisation 94. Two 
degenerate primers are used to amplify genomic regions between the repeat elements 95. 
Gel electrophoresis is used to separate the amplified DNA, generating a unique banding 
pattern which reflects the number of repetitive elements and length of DNA between them 96. 
This banding pattern can be used as a genetic fingerprint for each bacterial isolate. This 
technique is favoured as it is much less time consuming and laborious than other typing 
techniques. However, rep-PCR is susceptible to minor changes in reagents and conditions, 
making its reproducibility and portability problematic 81.  
PFGE was first described in 1984 and has since become a widely-used strain typing 
technique 97. It is considered to be the gold standard for typing bacteria 81. The restriction 
pattern of the whole genome is analysed using Restriction Enzymes (REs) with rare 
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recognition sites, resulting in a moderate number of large DNA fragments 97. As DNA 
fragments larger than 20 kb move at the same speed through agarose gel under 
conventional electrophoresis with a constant electric current, PFGE utilises alternating 
electric currents at different angles, capable of separating large fragments of up to 10 Mb 
93,97.  Continuously altering electrical currents re-orientates the DNA fragments and allows for 
separation of large fragments 93. The banding patterns of isolates can then be compared; 
isolates that differ by one to three bands differ by a single genetic event and are said to be 
closely related. If isolates differ by four to six bands they are considered possibly related as 
they differ by two independent genetic events. Isolates that differ by more than six bands are 
deemed unrelated 97. Unfortunately, this method is time-consuming and laborious and there 
are problems with reproducibility and portability across different laboratories 98.  
The aim of this section of the study was to describe the epidemiology of the collected 
Escherichia coli and Klebsiella pneumoniae isolates by performing rep-PCR and PFGE. This 
information could then be used to describe the relatedness of the circulating strains in this 
setting.  
2. Materials and methods 
2.1 Bacterial Isolates 
Strain typing was performed on all isolates collected as part of this study, including 70 E. coli 
and 70 K. pneumoniae; as described in Chapter 2. 
2.2 DNA extraction 
Bacterial isolates were retrieved from Microbank beads and cultured to obtain a pure culture. 
This was done by aseptically removing a single bead and streaking it onto a Tryptone Bile 
Agar (TBA) plate supplemented with horse blood (NHLS Media Laboratory, Greenpoint). The 
plate was incubated at 37°C overnight. A single colony from this plate was re-streaked onto 
a new TBA plate and incubated overnight at 37°C to obtain pure cultures. Colonies from this 
plate were used to perform a crude DNA extraction. An inoculum loop was used to remove 
culture from the plate which was then inoculated into 400 µl of nuclease free water in a 2 ml 
microcentrifuge tube (Eppendorf, Germany). This was vortexed to ensure a homogenous 
solution. The solution was heated at 95°C using a heating block (Accublock, Labnet, 
United States of America) and then frozen at -20°C in a freezer for 30 minutes. The solution 
was thawed and then centrifuged at 14000 x g for 10 minutes to remove cell debris. The 
supernatant containing the DNA was removed and placed in a new 1.5 ml microcentrifuge 
tube. All DNA extractions were stored at -20°C. 
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2.3 Rep-PCR 
Two degenerate primers were used to amplify repetitive consensus sequences (table 3.1); 
primers were synthesised by IDT (Integrated DNA Technologies, South Africa). The PCR 
was performed using extracted DNA and the KAPA2G Fast Multiplex PCR Kit (Kapa 
Biosystems, South Africa). All PCR reactions were performed using the ProFlex PCR system 
thermocycler (Applied Biosystems, United States of America). The cycling conditions were 
as follows: initial denaturation at 95°C for 5 minutes, 30 cycles of denaturation at 95°C for 30 
seconds, annealing at 40°C for 30 seconds and extension at 72°C for 8 minutes, followed by 
a final extension at 72°C for 16 minutes. The final primer concentrations were 0.8 pmol/µl for 
each primer. A reaction containing no template DNA (NTC) was included in each PCR run to 
ensure that there was no contamination. A control strain, ATCC25922 for E. coli and 
ATCC700603 for K. pneumoniae, was included in each gel to ensure reproducibility between 
PCR reactions and gels.   
Table 3.1: Primers used for the rep-PCR strain typing 94. 
Target  Primer Sequence (5’ – 3’) Product size 
(bp) 
Source 
REP REP1R-I 
REP2-I 
IIIICGICGICATCIGGC 
ICGICTTATCIGGCCTAC 
Multiple 
(100 – 2000 
bp) 
Versalovic et al. 
(1991). 
 
PCR products were separated on a 2% agarose gel run at 110V for 4 hours in a 1X TBE (89 
mM Tris, 89 mM borate, 2.5 mM EDTA) buffer. TBE buffer was used instead of TAE as it is 
more resistant to heat produced by the high voltage and longer running time. KAPA 
universal DNA Ladder (Kapa Biosystems, South Africa) was used as a molecular size 
marker on either side of the gel. PCR products were stained using NovelJuice (GeneDireX, 
South Africa) and the image was visualised and captured using the UVItec Alliance 2.7 gel 
documentation system (UVItec, United Kingdom). 
2.4 PFGE 
PFGE was performed at the Division of Medical Microbiology at Cardiff University in the 
United Kingdom as part of a research exchange.  
Preparation of bacterial isolates for shipment 
Isolates were streaked onto blood agar plates and cultured overnight at 37°C. The culture 
was inoculated onto BIO-CULT AMIES + charcoal swabs (Liofilchem, Italy) which were 
sealed using parafilm and packaged in UN 13373 containers. The swabs were sent to the 
United Kingdom at room temperature. Once the swabs arrived they were stored at 4°C. 
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Making the agarose plugs 
Bacterial isolates were streaked from swabs onto chromogenic agar to ensure purity. If the 
isolate was pure and the correct organism, i.e. K. pneumoniae or E. coli, a single colony 
from the plate was streaked onto Columbia agar supplemented with horse blood (E&O 
Laboratories limited, Scotland). Chromogenic agar could not be used as the pigmented 
culture may affect the PFGE result.  
The agarose used (1.5%) to cast the plugs was prepared with 0.006 g of SeaKem Gold 
agarose (Lonza, Switzerland) and 400 µl TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) per 
isolate tested. The mixture was microwaved until the agarose had dissolved (about 30 
seconds) and then the flask was placed into an oven at 50°C for at least 15 minutes to 
equilibrate. 
One millilitre of Cell Suspension Buffer (CSB) (100 mM Tris, 100 mM EDTA, pH 8.0) was 
dispensed into labelled 1.5 ml microcentrifuge tubes. Culture from the agar plates was 
inoculated into the CSB using a cotton swab to create a cell suspension with an optical 
density between 0.8-1.0 (600 nm). The optical density of the cell suspension was read by 
pipetting 800 µl of cell suspension into a cuvette and reading the optical density with a 
spectrophotometer (Jenway 7315 spectrophotometer). CSB was used to blank the 
spectrophotometer before use. 
The plug moulds were prepared by sealing the bottom of the plug mould using autoclave 
tape and labelling the moulds appropriately. Four hundred microliters of cell suspension was 
transferred into a 1.5 ml microcentrifuge tube. Twenty microliters of Proteinase K (20 mg/ml) 
(Sigma-Aldrich, United States of America) was added to each tube and mixed gently by 
pipetting up and down. The flask containing agarose was removed from the incubator and 
placed on top of a heating block set at 50°C to prevent the agarose from solidifying. Four 
hundred microliters of agarose was added to the cell suspension/Proteinase K mixture and 
this was mixed by pipetting up and down. This mixture was immediately dispensed into the 
wells of the plug mould, taking care to avoid bubbles in the well. This process was then 
repeated with the remaining cell suspensions. The plugs were left to solidify at room 
temperature for 15 minutes.  
Lysis and washing of the plugs 
A master mix of Cell Lysis Buffer (CLB) (50 mM Tris, 50 mM EDTA, pH 8.0 and with 1% 
Sarcosyl) and Proteinase K was made up for the lysis of the plugs. Five millilitres of CLB and 
25 µl Proteinase K was prepared per set of plugs. Five millilitres of the master mix was 
added to labelled 30 ml sterile universal containers.   
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Excess agarose was removed from the plug moulds using a scalpel sterilised with 70% 
ethanol and the tape was removed from the plug moulds. Plugs were pushed out of the 
mould into the labelled tubes, ensuring that the plugs were immersed in the  
CLB/Proteinase K mixture. Tubes were placed in a rack on a shaker and incubated at 50°C 
for 2 hours.  
After incubation, the CSB was poured off, taking care that no plugs were lost. The tubes 
were filled with 15 – 20 ml of autoclaved water, preheated to 50°C. The tubes were then 
placed in a rack on a shaker and incubated at 50°C for 15 minutes. This wash step was 
repeated once. 
The water in the tubes was poured off as before. Ten to fifteen millilitres of TE buffer 
preheated to 50°C was added to each tube. The tubes were returned to the shaker in the 
incubator for 15 minutes. The plugs were washed with heated TE buffer 3 more times. After 
the final wash, the TE buffer was poured off and 5 ml of fresh TE buffer was added to each 
tube and stored at 4°C until restriction digestion of the plugs.  
Restriction digestion of DNA in the plugs 
A master mix of diluted restriction buffer was made up of 20 µl of 10X FastDigest™ buffer 
(Thermo Scientific, United States of America) and 180 µl molecular grade water per isolate; 
and 200 µl of this master mix was added to labelled 1.5 ml microcentrifuge tubes.  
An agarose plug was carefully removed from the TE buffer and placed on a sterile slide. The 
plug was cut into 4 equal slices using a scalpel that had been sterilised in 70% ethanol.  The 
plug slices were transferred into the microcentrifuge tube (Eppendorf) containing the diluted 
restriction buffer, ensuring that all plug slices were at the bottom of the tube and covered by 
the diluted restriction buffer mixture. The plug slices were incubated at room temperature for 
15 minutes. The buffer mixture was then removed from the microcentrifuge tubes 
(Eppendorf) using a pipette. A restriction enzyme master mix was made up using 175 µl 
molecular grade water, 20 µl of 10X FastDigest buffer and 5 µl XbaI enzyme (10 U/ µl) 
(Thermo Scientific) per set of plugs. Two hundred microliters of this master mix was added 
to each tube and the tubes were incubated in a heating block at 37°C for 2 hours.  
After incubation, the digestion master mix was removed from the tubes using a pipette and 
200 µl of 0.5 M EDTA, pH 8.0 was added to each tube to preserve the prepared plugs. 
Casting and loading the gel 
A 1% agarose gel was made by weighing 1.2 g of agarose (Sigma-Aldrich, United States of 
America) and placing it into a bottle with 120 ml of 0.5X TBE (prepared from 10X TBE stock). 
The mixture was microwaved until the agarose had dissolved. The bottle was then placed in 
Stellenbosch University  https://scholar.sun.ac.za
38 
 
an oven set at 50°C to equilibrate for at least 15 minutes. The casting stand was prepared 
and fitted with a 15 well gel comb.  Twenty microliters of ethidium bromide (0.5 μg/ml) was 
added to the gel and mixed before the gel was poured into the casting stand. The gel was 
left to set for 30 minutes at room temperature.  
After the gel had solidified, the comb was removed from the gel. The CHEF DNA size 
standard Lambda Ladder (Bio-Rad, United States of America) was used as a ladder in each 
gel. A plug was removed from the tube and cut to the appropriate size. The plug slices with 
Lambda Ladder were loaded into the 1st and 15th well of the gel using a scalpel and 
disposable loop. Plug slices containing bacterial DNA were removed from the 
microcentrifuge tubes containing EDTA and loaded into the remaining wells in a similar 
manner. A specific bacterial isolate was used as a control in each gel to compare variation 
between gels; for K. pneumoniae it was GN10 and for E. coli it was GN8.  
After the gel had been loaded with the agarose plugs, it was removed with the gel tray from 
the casting stand. Excess agarose was removed from the sides and bottom of the gel tray.  
Electrophoresis  
Two litres of 0.5X TBE was added to the electrophoresis chamber and 50 ml of ethidium 
bromide was added to the buffer. The CHEF DR-III system, pump and cooling unit (10°C) 
(Bio-Rad, United States of America) were turned on. The buffer was allowed to circulate 
through the system for at least 30 minutes before running the gel to allow it to cool. The 
buffer was used until the current reached 300V and was then replaced. After each 
replacement, the system was flushed with 0.5X TBE buffer and water. The gel frame was 
secured in the electrophoresis chamber. The prepared gel on the gel tray was placed inside 
the gel frame and the cover of the chamber was closed.  
The CHEF DR-III system was set to the conditions below. 
 Initial switch time: 5 seconds 
 Final switch time: 45 seconds 
 Voltage: 6 V 
 Included angle: 120° 
 Run time: 23 hours 
After the electrophoresis was complete, the gel and gel tray were removed from the 
electrophoresis chamber and an image of the gel was captured using the Gel Doc-It imaging 
system (UVP, United States) and VisionWorksLS software (UVP).  
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2.5 Analysis of rep-PCR and PFGE gels 
The gel images were uploaded into BioNumerics 7.5 (Applied Maths, United States of 
America). This program enables the analysis of gel images to create phylogenetic trees and 
determines the relatedness of strains. Images are uploaded into the program; the ladder is 
marked and the specific band sizes are entered. The banding patterns of the isolates are 
recognised and marked individually. This information is then used to generate a phylogenetic 
tree. The similarity coefficient used was Dice and the clustering method used was 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA).  
For PFGE, clustering was assessed at 70% and 95% similarity thresholds as this is 
represents a difference of four to six bands (possibly related) and one to three bands 
(closely related) respectively 99. For rep-PCR, many studies use 95% threshold to define 
isolates as closely related 100–102. In this study, a second threshold of 70% was used to 
define isolates that are possibly related to correlate with the PFGE cut-off.  
2.6 Comparison of typing methods 
Simpson’s index of diversity was used to compare the diversity between the two strain typing 
methods. This was calculated as 1 – D, where D represents Simpson’s Index. Simpson’s 
index was calculated using the following formula;  
∑𝑛(𝑛−1)
𝑁(𝑁−1)
 where n is the total number of 
isolates in a cluster and N is the total number of clusters. This index was chosen as it takes 
into account the number of clusters present as well as the number of isolates in each cluster, 
thereby evaluating the richness and evenness of the population. This index represents the 
probability that two randomly selected isolates will fall into different clusters 103. The closer 
the value is to one, the higher the diversity.  
3. Results 
3.1 Rep-PCR 
All 140 E. coli and K. pneumoniae isolates were typed by rep-PCR. An example of the gel 
images obtained can be seen in figure 3.1.  
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Figure 3.1: Rep-PCR gel image. Lanes 1 and 17 contain the KAPA universal DNA ladder. Lanes 2 -14 
are clinical isolates. Lane 15 contains a control isolate, ATCC700603 and lane 16 is a NTC. 
The phylogenetic trees generated for E. coli and K. pneumoniae can be seen in figure 3.2 
and 3.3 respectively. Little clustering was seen in both the E. coli and K. pneumoniae 
isolates, with isolates not clustering according to the wards in which the patients were 
located, or between hospital- or community-acquired infections. For E. coli, a 70% threshold 
identified 16 clusters and 23 singletons. The largest cluster contained seven isolates, 
although most clusters (9/16) contained only two isolates. A cut-off of 95% identified one 
cluster of two isolates with identical banding patterns (GN58 and GN59) and 68 singletons. 
For K. pneumoniae, a threshold of 70% identified 16 clusters and 20 singletons. The largest 
cluster was made up of nine isolates, but most of the clusters (11/16) were made up of two 
isolates. A 95% threshold identified two clusters of two isolates and the remaining 66 
isolates were singletons. Two pairs of identical isolates, GN90 and GN91, and GN27 and 
GN32, were identified.  
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Figure 3.2: Phylogenetic tree generated from rep-PCR results for E. coli isolates. 
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Figure 3.3: Phylogenetic tree generated from rep-PCR results for K. pneumoniae isolates. 
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3.2 PFGE 
As isolates were being cultured from swabs shipped to Cardiff University, contamination was 
noticed among some isolates. Therefore, isolates were first swabbed onto selective 
chromogenic media to determine whether they were contaminated. Where possible, 
contaminated isolates were purified; unfortunately, 8 isolates, GN26, GN43, GN64, GN66, 
GN72, GN128, GN129 and GN139, could not be tested by PFGE as the swabs contained 
only contaminants. One E. coli isolate, GN67 failed PFGE twice despite re-extraction of DNA 
and was also excluded from analysis. Ultimately, 65 E. coli and 66 K. pneumoniae isolates 
were included in the PFGE analysis. An example of a PFGE gel image can be seen below in 
figure 3.4. All gels were run with the CHEF DNA size standard Lambda Ladder one either 
side to use as a marker when analysing gels. Unfortunately, the ladder was unclear in some 
gel images, therefore the bacterial isolate ran in every gel, i.e. GN8 (E. coli) or GN10  
(K. pneumoniae), was used as the marker.  
 
Figure 3.4: PFGE gel image. Lanes 1 and 15 contain the CHEF DNA size standard Lambda ladder. 
Lanes 2 -14 are clinical isolates. Lane 2 contains the control isolate for E. coli, GN8. 
The phylogenetic trees for E. coli and K. pneumoniae, generated from the PFGE results, can 
be seen in figures 3.5 and 3.6 respectively. As with the rep-PCR results, minimal clustering 
was seen in E. coli or K. pneumoniae isolates. Isolates did not cluster according to the wards 
from which they were isolated, or between hospital- or community-acquired infections. When 
examining the phylogenetic tree of E. coli isolates using a cut-off value of 70%, there were 6 
clusters of two isolates and 53 singletons. When using a cut-off of 95% there were two 
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clusters of two isolates and 61 singletons. Two isolates, GN58 and GN59 were identified as 
identical (and had also been identified as identical by rep-PCR). When examining K. 
pneumoniae using a cut-off of 70% there were 6 clusters and 50 singletons. The largest 
cluster was made up of 5 isolates, but most of the clusters (4/6) were made up of 2 isolates. 
When using a 95% cut-off there were two clusters of two isolates and 62 isolates singletons. 
Two isolates were identified as identical, namely GN50 and GN51 – which, interestingly, 
differs from the isolates identified as identical by rep-PCR. 
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Figure 3.5: Phylogenetic tree generated from PFGE results for E. coli isolates. 
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Figure 3.6: Phylogenetic tree generated from PFGE results for K. pneumoniae isolates. 
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3.3 Comparison of typing methods 
The Simpson’s Index of Diversity was calculated for E. coli and K. pneumoniae for each 
strain typing technique at two thresholds, 70% and 95% similarity. The Simpson’s index of 
diversity was higher at a 95% similarity cut-off. This index was also higher for PFGE 
compared to rep-PCR (Table 3.2, Figure 3.7).  
Table 3.2: Simpson’s index of diversity for rep-PCR and PFGE. 
Typing method and 
bacterial species 
Total 
number of 
isolates 
Cut-off Number of 
clusters 
Number of 
singletons 
Simpson’s 
index of 
diversity 
Rep-PCR E. coli 70 70% 16 23 0.9150 
95% 1 68 0.9996 
PFGE E. coli 65 70% 6 53 0.9965 
95% 2 61 0.9990 
Rep-PCR K. pneumoniae 70 70% 16 20 0.8587 
95% 2 66 0.9991 
PFGE K. pneumoniae 66 70% 6 50 0.9890 
95% 2 62 0.9990 
 
 
Figure 3.7: Simpson's Index of Diversity (SID) values of rep-PCR and PFGE for E. coli and K. 
pneumoniae. 
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4. Discussion 
Strain typing of the E. coli and K. pneumoniae isolates collected from BSI at Tygerberg 
Hospital over the period of a year provides important epidemiological information about the 
bacterial strains causing bloodstream infections in our setting. PFGE remains the gold 
standard technique for strain typing. This method is laborious and requires four days to 
obtain a result, however it provides high levels of discrimination as it evaluates the entire 
bacterial genome. rep-PCR is a strain typing technique with a shorter turnaround time and 
simpler methodology. It is a viable alternative to PFGE for large sample groups and when 
information is required rapidly (e.g. a possible outbreak) 99. Brolund et al. recommends using 
rep-PCR as a primary screening method to exclude unrelated isolates, then using a more 
discriminatory method to investigate related isolates 104.  
Phylogenetic trees generated from both strain typing techniques show that the E. coli and  
K. pneumoniae isolates included in this study are genetically diverse. Two thresholds were 
used to analyse the relatedness of isolates; the cut-off of 70% represents isolates that are 
possibly related, while 95% represents isolates that are closely related 99. As expected, 
increased discrimination and more diversity was seen at the 95% threshold for both typing 
techniques. For E. coli and K. pneumoniae with both strain typing techniques, the number of 
clusters decreased and the number of singletons increased when the threshold was raised 
from 70% to 95%; this was also demonstrated by the higher value of Simpson’s Index of 
Diversity. However, these differences were more prominent in rep-PCR as compared to 
PFGE. This may be due to the fact that PFGE is a more discriminatory method than rep-
PCR and divides the isolates into more genetic lineages 104. Rep-PCR may be 
overestimating the genetic relatedness of these isolates. The increased discrimination of 
PFGE and increased clustering of isolates by rep-PCR has been observed in other studies 
99,100,104.   
Both rep-PCR and PFGE identified the E. coli isolates GN58 and GN59 as identical. For  
K. pneumoniae there were discrepancies in the isolates that were identified as identical by 
rep-PCR and PFGE. Rep-PCR denoted GN27 and GN32 as well as GN90 and GN91 as 
identical, while PFGE identified GN50 and GN51 as identical. According to the PFGE 
results, GN27 and GN32 are not closely related, although GN90 and GN91 are (70.6% 
relatedness); this likely reflects the better discriminatory ability of PFGE. Rep-PCR did not 
cluster GN50 and GN51 closely. Studies by Koroglu et al. and Hahm et al. also found 
discrepancies between the two methods in terms of identifying certain isolates as identical 
and certain isolates as singletons 100,105. Hahm et al. evaluated a number of typing 
techniques, such as PFGE, rep-PCR, multiplex-PCR, ribotyping and Amplified Fragment 
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Length Polymorphism (AFLP), and found that the different methods did not group the 
isolates identically and isolates were found in different positions on the phylogenetic  
trees 105. This indicates that the typing methods reveal different information about the 
phylogenetic relationships of the tested isolates. This is probably due to the fact that the 
various typing methods target different genetic regions.  
In addition to the genetic diversity amongst isolates, isolates did not cluster according to the 
wards from which they were isolated, or between hospital- or community-acquired infections 
or by phenotypic ESBL production.  Other studies have reported similar diversity amongst 
isolates. Studies in Taiwan and Thailand investigated the relatedness of ESBL producing  
E. coli and K. pneumoniae isolates from clinical specimens by PFGE and found the isolates 
to be genetically divergent 106,107. Both studies examined only ESBL producing isolates from 
all clinical specimens, which were identified by disc diffusion. Lin et al. used a threshold of 
75% to determine similarity, while Kiratisin et al. used a threshold of 80% to identify related 
isolates and a 60% threshold to identify distantly related isolates. Both studies concluded 
that ESBL producing E. coli and K. pneumoniae isolates are polyclonal in their setting and 
speculate that resistance genes are being transferred among isolates. A Spanish study 
looking at ESBL producing E. coli from bloodstream infections found the isolates to be 
unrelated by rep-PCR and PFGE 108. The E. coli isolates with similar rep-PCR patterns were 
investigated further by PFGE, although the threshold values for similarity were not stated. 
This study concluded that patients were most probably colonised by the bacteria and 
developed infection whilst in hospital. Another Spanish study focused on ESBL producing  
E. coli and K. pneumoniae found isolates to be highly diverse by rep-PCR 109. However, the 
study did find that K. pneumoniae isolates in some hospitals were clonally related, although 
they did not indicate in how many of the 40 healthcare centres this was observed. The 
authors noted that K. pneumoniae isolates are often involved in outbreaks.  
On the other hand, various studies have demonstrated that bacteria isolated from infections 
are closely related. For example, an American study focused on ceftazidime resistant E. coli 
and K. pneumoniae isolates causing BSIs, found the isolates to be part of a poly-clonal 
outbreak, using PFGE 110. The majority of the patients in this study were in nursing homes 
and the investigators speculate that cross-contamination occurred via a common source. A 
study conducted in South Africa looking at infections with ESBL producing E. coli found that 
almost half (45%) of the isolates belonged to the highly successful E. coli clonal complex 
ST131 111. Although most of the isolates were from urine specimens and the sample size 
was small (n=24).  
MLST is another strain typing method which provides additional value as it identifies defined 
strain types and allows comparison to other epidemiological studies and MLST databases 
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112. Due to the large amount of sequencing required for this method, we had initially planned 
to perform MLST on selected representative isolates from the larger clusters (identified by 
PFGE or rep-PCR). However, the results of the typing showed no predominant clusters, and 
this approach was abandoned as it would have required performing MLST on the majority of 
isolates.  
5. Conclusion 
The collected isolates were typed by two strain typing techniques, providing some insight 
into the epidemiology of E. coli and K. pneumoniae strains causing BSIs in this setting. The 
results from both strain typing techniques demonstrate that the isolates in this study are 
genetically diverse, with little clustering. The diversity of circulating E. coli and K. 
pneumoniae strains suggests that patient-to-patient transmission of bacteria or 
contamination of the environment is not the main cause of BSIs. Due to the diverse bacterial 
strains causing infection, it makes it difficult to ascertain transmission routes and implement 
controls to reduce the number of BSIs. While the lack of a common circulating clone/s may 
suggest less ongoing transmission of the organisms (and thus suggests adequate infection 
prevention and control (IPC) measures), further studies would be required to better 
understand the transmission dynamics of these organisms, which may further inform IPC 
activities.  
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Chapter 4: Resistance genes  
1. Introduction 
Resistance to β-lactam antibiotics in Enterobacteriaceae is most often as a result of the 
production of plasmid mediated β-lactamase enzymes, such as Extended-Spectrum β-
lactamases (ESBLs) and carbapenemases 52. Understanding the molecular epidemiology of 
these resistance genes is important to define the impact of these resistance mechanisms 
and it may also assist in guiding correct empiric treatment 101. 
The β-lactamases TEM-1, TEM-2 and SHV-1 are the progenitors for the TEM and SHV 
ESBLs respectively and are not able to hydrolyse the extended-spectrum β-lactams. While 
TEM- and SHV-related ESBLs may differ by only a few amino acids from their respective 
progenitors, these changes can result in a substantial change in enzymatic ability 22. TEM 
and SHV β-lactamases can be divided into three groups based on their functional properties 
or phenotype 53,113. The first group can hydrolyse penicillins and early cephalosporins and 
are strongly inhibited by β-lactamase inhibitors like clavulanic acid and tazobactam. 
Examples include TEM-1, TEM-2, TEM-12, SHV-1, SHV-11 and SHV-89. The second group 
has the same hydrolysis profile as the first but are resistant to clavulanic acid. TEM β-
lactamases with this phenotype as also known as Inhibitor Resistant TEMs (IRT). TEM-30, 
TEM-31, SHV-10 and SHV-72 are examples of IRT TEMs. The third group is made up of 
ESBLs, which are able to hydrolyse penicillins, early and extended-spectrum cephalosporins 
but remain sensitive to inhibition by clavulanic acid. Examples include TEM-3, TEM-10, 
SHV-2 and SHV-115. All CTX-M ESBLs also fall into this group. 
In earlier studies β-lactamase genes were analysed biochemically by isolating the protein 
and determining its isoelectric point by isoelectric focusing and then performing enzymatic 
studies to identify the hydrolysis and inhibition profile of the gene 65. Currently molecular 
methods such as Polymerase Chain Reaction (PCR), sequencing, probes and PCR-
Restriction Fragment Length Polymorphism (PCR-RFLP) are mostly used to identify β-
lactamase genes.  
Databases have been created to standardize the nomenclature for the growing number of β-
lactamases (http://www.lahey.org/studies, http://www.laced.uni-stuttgart.de/) 53. These 
databases contain information about TEM and SHV β-lactamases such as their phenotype, 
specific amino acid substitutions and GenBank accession numbers for the specific genes. 
These databases are valuable as they provides important information about the majority of 
the TEM and SHV β-lactamases. Unfortunately not all of these β-lactamases have been 
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characterised and some have been withdrawn or are invalid 113. It is not clear whether 
measures are in place to address these deficits.  
The aim of this component of the study was to determine the prevalence of ESBLs and 
carbapenamases in the collected set of isolates, and to further characterize the types of 
ESBLs and carbapenemases by a combination of PCR and sequence analysis.  
2. Methods and materials 
2.1 Bacterial isolates and controls 
All Escherichia coli and Klebsiella pneumoniae isolates previously described in chapter two 
were screened for resistance genes. DNA was extracted from these isolates as described in 
chapter 3. 
A previously characterised control strain containing all three ESBL genes was supplied by Dr 
C. Moodley from the NHLS National Institute for Communicable Diseases (NICD) satellite 
unit at Groote Schuur Hospital. Control strains containing all the screened carbapenemase 
genes were obtained from the NICD. Extracted DNA from these controls was combined to 
maximise space available for testing isolates. 
2.2 PCR amplification of β-lactamase genes  
All isolates were screened for the three β-lactamase gene families, blaTEM, blaSHV and  
blaCTX-M, using a multiplex PCR. Specific primers were used for each family and an internal 
amplification control, rpoB, was included (Table 4.1). The internal amplification control 
indicates that the PCR reaction was successful and DNA quality is adequate. Primers were 
synthesised by IDT (Integrated DNA Technologies, South Africa). The KAPA2G Fast 
Multiplex PCR Kit (Kapa Biosystems, South Africa) was used and 1 µl of bacterial DNA was 
used for each reaction. All PCR reactions were performed using the ProFlex PCR system 
thermocycler (Applied Biosystems, United States of America). The PCR amplification 
conditions were as follows: initial denaturation at 95°C for 3 minutes, 35 cycles of 
denaturation at 95°C for 15 seconds, annealing at 67°C for 30 seconds and extension at 
72°C for 30 seconds, followed by a final extension at 72°C for 3 minutes. Final primer 
concentrations were 0.2 pmol/µl for all primers except primers for blaSHV which were 0.24 
pmol/µl. A no-template control (NTC) containing no bacterial DNA was included in each PCR 
to exclude contamination.  
Gel electrophoresis of the PCR products was performed using the PowerPac Basic power 
supply system (Bio-Rad, South Africa). PCR products were separated using a 2-2.5% 
agarose gel run at 100V for 90 minutes in a Tris-acetic acid-EDTA (TAE) buffer, and using 
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KAPA universal DNA Ladder (Kapa Biosystems, South Africa) as a molecular size marker. 
Agarose gels were stained using NovelJuice (GeneDireX, South Africa) and the image was 
visualised and captured using the UVItec Alliance 2.7 gel documentation system (UVItec, 
United Kingdom). 
Table 4.1: Primers used for the ESBL multiplex PCR 114,115. 
Target 
gene 
Primer Sequence (5’ – 3’) Product 
size (bp) 
Source 
blaTEM TEM-164.SE 
TEM-165.AS 
TCGCCGCATACACTATTCTCAGAATGA 
ACGCTCACCGGCTCCAGATTTAT 
445 Monstein et al. 
(2007) 
blaSHV bla-SHV.SE  
bla-SHV.AS 
ATGCGTTATATTCGCCTGTG 
TGCTTTGTTATTCGGGCCAA 
747 Monstein et al. 
(2007) 
blaCTX-M CTX-M-U1 
CTX-M-U2 
ATGTGCAGYACCAGTAARGTKATGGC 
TGGGTRAARTARGTSACCAGAAYCAGCGG 
593 Monstein et al. 
(2007) 
rpoB rpoB-F 
rpoB-R 
AACCAGTTCCGCGTTGGCCTGG 
CCTGAACAACACGCTCGGA 
1088 Hoffmann and 
Roggenkamp 
(2003) 
 
2.3 TEM and SHV characterisation 
All TEM and SHV amplification products (section 2.2) were sequenced to further 
characterise the genes. A single-plex PCR was performed using either the TEM or SHV 
primers listed in section 2.2 as appropriate, using KAPA2G Fast Multiplex PCR Kit (Kapa 
Biosystems). The PCR amplification conditions were similar to the ESBL PCR: initial 
denaturation at 95°C for 3 minutes, 35 cycles of denaturation at 95°C for 15 seconds, 
annealing at 65°C for 30 seconds and extension at 72°C for 30 seconds, followed by a final 
extension at 72°C for 3 minutes. In these single-plex assays the final primer concentrations 
were 0.4 pmol/µl for all primers. Gel electrophoresis was performed on all PCR products as 
described above in section 2.2, to ensure amplification was successful.  
The PCR products were sent for sequencing at Inqaba Biotech (South Africa) using the 
forward primers. Sequencing results were analysed using the BioEdit Sequence Alignment 
Editor 116. Sequences of amplification products for the TEM-related genes were compared to 
TEM-1, TEM-2 and ESBL TEM sequences downloaded from National Centre for 
Biotechnology Information (NCBI) 117. SHV amplification product sequences were identified 
by translating the DNA sequences to amino acid sequences and analysing them through the 
BLAST database 118. Amino acid sequences were used for SHV analysis as the DNA 
sequences contained numerous nucleotide substitutions and it was not known which were 
synonymous and which were nonsynonymous. If further discrimination was needed, 
sequences were compared to SHV sequences downloaded from NCBI 117. 
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2.4 Characterisation of CTX-M genes 
All isolates that were positive for CTX-M genes in the β-lactamase PCR, were further tested 
to classify the CTX-M enzyme/s into the five CTX-M sub-groups. Specific primers for each of 
these groups were used, with Groups 8 and 25 using a shared reverse primer (Table 4.2). 
Primers were synthesised by IDT (Integrated DNA Technologies). The multiplex PCR was 
performed using the KAPA2G Fast Multiplex PCR Kit (Kapa Biosystems) and the ProFlex 
PCR system thermocycler (Applied Biosystems). The cycling conditions were as follows: 
initial denaturation at 95°C for 3 minutes, 30 cycles of denaturation at 95°C for 15 seconds, 
annealing at 60°C for 30 seconds and extension at 72°C for 30 seconds, followed by a final 
extension at 72°C for 3 minutes. Final primer concentrations were 0.2 pmol/µl for all primers. 
PCR products were run on an agarose gel and visualised as described in section 2.2. A NTC 
containing no bacterial DNA was included in each PCR performed to confirm that there was 
no contamination. Controls were not available; therefore selected amplification products 
were sent for sequencing to confirm correct amplification. These isolates could then be used 
as controls in successive PCR reactions. Isolates showing ambiguous results were retested 
using a singleplex PCR with each primer pair, using the cycling conditions listed for the 
multiplex PCR, and products were sent for sequencing at Inqaba Biotech (South Africa) to 
confirm results.  
Table 4.2: Primers used for the CTX-M multiplex PCR 119. 
blaCTX-M 
subgroup 
Primer Sequence (5’ – 3’) Product size 
(bp) 
Group 1 CTX-M G1-F 
CTX-M G1-R 
AAAAATCACTGCGCCAGTTC 
AGCTTATTCATCGCCACGTT 
415 
Group 2 CTX-M G2-F 
CTX-M G2-R 
CGACGCTACCCCTGCTATT 
CCAGCGTCAGATTTTTCAGG 
552 
Group 8  CTX-M G8-F 
CTX-M G8/25-R 
TCGCGTTAAGCGGATGATGC 
AACCCACGATGTGGGTAGC 
666 
Group 9 CTX-M G9-F 
CTX-M G9-R 
CAAAGAGAGTGCAACGGATG 
ATTGGAAAGCGTTCATCACC 
205 
Group 25 
 
CTX-M G25-F 
CTX-M G8/25-R 
GCACGATGACATTCGGG 
AACCCACGATGTGGGTAGC 
327 
 
2.5 Amplification of carbapenemase genes 
A multiplex PCR was used to screen all isolates for selected carbapenemase genes. The 
carbapenemase genes blaIMP, blaKPC, blaNDM, blaOXA-48 and blaVIM along with an internal 
amplification control, rpoB, were amplified using specific primers (Table 4.3). Primers were 
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synthesised by IDT (Integrated DNA Technologies). The KAPA2G Fast Multiplex PCR Kit 
(Kapa Biosystems) was used and the PCR conditions were optimised to a touchdown PCR 
to minimise non-specific binding of primers. All PCR reactions were performed using the 
ProFlex PCR system thermocycler (Applied Biosystems). The cycling conditions were as 
follows: initial denaturation at 95°C for 3 minutes, 20 cycles of denaturation at 95°C for 15 
seconds, annealing at 68°C for 30 seconds and extension at 72°C for 1 minute, followed by 
10 cycles of denaturation at 95°C for 15 seconds, annealing at 62°C for 30 seconds and 
extension at 72°C for 1 minute and lastly, a final extension at 72°C for 5 minutes. Final 
primer concentrations were 0.2 pmol/µl for all carbapenemase gene primers and 0.08 
pmol/µl for internal control primers. A NTC was included in each PCR run, to ensure that 
there was no contamination present. Gel electrophoresis was performed on all PCR 
products as described in section 2.2. PCR products were run on an agarose gel and 
visualised as mentioned in section 2.2.  
Table 4.3: Primers used for the carbapenemase PCR 102,115. 
Target 
gene 
Primer Sequence (5’ – 3’) Product 
size (bp) 
Source 
blaIMP IMP-F 
IMP-R 
CTACCGCAGCAGAGTCTTTGC 
GAACAACCAGTTTTGCCTTACC 
591 Zowawi et al. 
(2014). 
blaKPC KPC-F 
KPC-R 
ATCTGACAACAGGCATGACG 
GACGGCCAACACAATAGGTG 
452 Zowawi et al. 
(2014). 
blaNDM NDM-F 
NDM-R 
GCAGGTTGATCTCCTGCTTG 
ACGGTTTGGCGATCTGGT 
203 Zowawi et al. 
(2014). 
blaOXA-48 OXA-48-F 
OXA-48-R 
GCGTGGTTAAGGATGAACAC 
CATCAAGTTCAACCCAACCG 
438 Zowawi et al. 
(2014). 
blaVIM VIM-F 
VIM-R 
GATGGTGTTTGGTCGCATA 
CGAATGCGCAGCACCAG 
390 Zowawi et al. 
(2014). 
rpoB rpoB-F 
rpoB-R 
AACCAGTTCCGCGTTGGCCTGG 
CCTGAACAACACGCTCGGA 
1088 Hoffmann and 
Roggenkamp 
(2003) 
  
3. Results 
3.1 Amplification of β-lactamase genes 
A multiplex PCR adapted from Monstein et al. was used to screen all isolates for the β-
lactamase genes blaTEM, blaSHV and blaCTX-M as well as an internal control, rpoB  114,115. The 
PCR conditions were optimised to reduce non-specific binding as far as possible. A 
representative image of an electrophoresis gel can be seen in figure 4.1.  
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Figure 4.1: Multiplex PCR identification of β-lactamase genes. Lanes 1 and 11 contain the KAPA 
universal DNA ladder, lanes 2- 8 are clinical isolates; the positive control in lane 9 shows the desired 
amplification products for SHV, TEM and CTX-M genes and the internal control, rpoB, at 1100bp; lane 
10 is the NTC. 
The overall distribution of β-lactamase genes was as follows; in 53.6% (75/140) of isolates 
one β-lactamase family was detected, while 16.4% (23/140) of isolates contained two β-
lactamase family genes and 16.4% (23/140) contained all three gene families. No β-
lactamase genes were detected in 13.6% (19/140) of isolates (Figure 4.2). 
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Figure 4.2: Graphical representation of the β-lactamase genes detected in isolates. 
The distribution of β-lactamase genes differed between E. coli and K. pneumoniae isolates 
(p<0.01) (figure 4.3). E. coli isolates mainly contained TEM genes alone (45/70) or no β-
lactamase genes (15/70). K. pneumoniae isolates showed more variation in β-lactamase 
genes with the most common profiles being a combination of all three β-lactamase genes 
(23/70) or SHV genes alone (21/70). 
 
Figure 4.3: Distribution of β-lactamase genes in E. coli and K. pneumoniae isolates. 
21; 15%
47; 34%
7; 5%
7; 5%
10; 7%
6; 4%
23; 16%
19; 14%
SHV
TEM
CTX-M
SHV, TEM
CTX-M, TEM
SHV, CTX-M
SHV, CTX-M, TEM
None
0
45
6
4
0 0 0
15
21
2 1
6 6 7
23
4
0
5
10
15
20
25
30
35
40
45
SHV TEM CTX-M CTX-M, TEM SHV, CTX-M SHV, TEM SHV, CTX-M,
TEM
None
N
u
m
b
e
r 
o
f 
is
o
la
te
s
β-lactamase resistance genes
E. coli
K. pneumoniae
Stellenbosch University  https://scholar.sun.ac.za
58 
 
3.2 TEM and SHV characterisation 
All TEM and SHV PCR products were sequenced to determine whether the genes were 
ESBLs or not. The results are summarised in table A.1 in appendix A. Eighty-seven isolates 
were positive for TEM genes, of which 86 amplification products were successfully 
sequenced and were included in the analysis. The sequence quality for isolate GN9 was too 
poor to analyse properly. The 86 sequences were compared to TEM-1, TEM-2 and ESBL 
TEM genes obtained from the GenBank database. Eighty-one (94.2%) of the TEM genes 
were found to be TEM-1, 3 (3.5%) had one nucleotide difference from TEM-1 and were 
found to be TEM-2. Only two (2.3%) TEM genes were ESBL TEM genes, however the 
specific TEM genes could not be identified as the sequenced products were too short. 
Fifty-seven isolates were positive for SHV genes, all of which were successfully sequenced. 
These sequences were translated to amino acid sequences and identified using the BLAST 
database (table 4.4). The SHV amino acid sequences of a few isolates were identical to 
more than one SHV protein, such as SHV-14 and SHV-161 as well as SHV-1, SHV-28 and 
SHV-125. These isolates’ SHV nucleotide sequences were then compared to those SHV 
gene sequences, downloaded from the NCBI database.  
As displayed in table 4.4, the most common SHV genes were SHV-125 (42.1%) and SHV-11 
(33.3%). According to the Lahey database, the SHV genes SHV-1, SHV-11, SHV-14, SHV-
26, SHV-33, SHV-62 and SHV-76 are some of the genes that do not possess ESBL activity 
53. The SHV genes SHV-28, SHV-125, SHV-137 have not yet had their phenotype 
described. In table 4.4 the data was divided according to activity of the SHV genes. 
Therefore, 4/57 (7%) of the SHV genes from our study have previously confirmed ESBL 
activity, 27/57 (47.4%) have only narrow spectrum β-lactamase activity and for 26/57 
(45.6%) of genes, it is not clear whether these gene products have extended-spectrum 
activity.  
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Table 4.4: Distribution of SHV genes. 
ESBL 
activity 
SHV 
gene 
Nr of 
isolates 
Isolates Total nr of 
isolates  
Non ESBL SHV-1 1 GN116 27 (47.4%) 
SHV-11 19 GN5, GN11, GN13, GN27, GN32, GN39, GN40, 
GN41, GN50, GN51, GN56, GN78, GN92, 
GN101, GN112, GN134, GN135, GN137, 
GN143 
SHV-14 3 GN10, GN93, GN140 
SHV-26 1 GN36 
SHV-33 1 GN128 
SHV-62 1 GN68 
SHV-76 1 GN125 
ESBL SHV-2 1 GN23 4 (7%) 
SHV-5 1 GN94 
SHV-126 2 GN21, GN38 
Unknown 
activity 
SHV-28 1 GN103 26 (45.6%) 
SHV-125 24 GN6, GN7, GN17, GN28, GN31, GN35, GN48, 
GN49, GN53, GN57, GN60, GN65, GN73, 
GN77, GN97, GN109, GN110, GN113, GN115, 
GN126, GN127, GN130, GN139, GN144 
SHV-137 1 GN3 
 
The β-lactamase PCR and sequencing results were analysed together and summarised 
below in table 4.5. The most commonly seen β-lactamase gene in E. coli was TEM β-
lactamases; only 11 (15.7%) E. coli isolates contained ESBL genes. K. pneumoniae isolates 
had a variety of resistance gene profiles, with the most common β-lactamase genes being 
SHV ESBLs and SHV β-lactamases. Only four (5.7%) of E. coli isolates contained multiple 
β-lactamase genes, while 42 (60%) of K. pneumoniae contained multiple β-lactamase 
genes. A table showing the detailed distribution of β-lactamase and ESBL genes can be 
seen in appendix A (figure A.1).  
Table 4.5: Distribution of β-lactamase genes with and without extended-spectrum activity among  
E. coli and K. pneumoniae isolates 
 
E. coli (n=70) K. pneumoniae (n=70) Total (n=140) 
No β-lactamase genes 15 4 19 
β-lactamase genes with no extended-
spectrum activity a 
44 27 71 
β-lactamase/s genes 
with extended-
spectrum activity b 
 
TEM ESBL 1 1 2 
SHV ESBL 0 2 2 
CTX-M 10 34 44 
SHV ESBL & CTX-M 0 2 2 
Any ESBL 11 (15.7%) 39 (55.7%) 50 (35.7%) 
 
a: This includes TEM-1, TEM-2, and all SHV genes either known or suspected not to have extended activity, as 
detailed in the text. 
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b: For isolates containing multiple genes where one has extended-spectrum activity and one or more, only the 
gene/s with extended-spectrum activity are shown. 
3.3 Characterisation of CTX-M genes 
All isolates that were positive for CTX-M genes in the β-lactamase PCR, were further tested 
to classify the CTX-M enzymes into the five different CTX-M sub-groups. Forty-six isolates 
demonstrated the presence of CTX-M genes in the multiplex β-lactamase PCR. Forty-two 
(91.3%) of these belonged to CTX-M group 1, three (6.5%) belonged to group 9 and one 
isolate, GN9, was untypeable. This isolate had abnormal bands present; subsequently each 
of the assays in the multiplex CTX-M PCR was performed as a singleplex assay to further 
investigate this result. The amplification products of the singleplex PCRs did not match what 
was seen in the multiplex CTX-M PCR. The singleplex PCR products were sent for 
sequencing; the amplified products were not β-lactamase genes as they were identified as a 
major facilitator superfamily (MFS) transporter, which is a membrane transport protein. The 
amplified products were interpreted as non-specific binding. 
3.4 Amplification of carbapenemase genes 
All isolates were screened for carbapenemase genes using a multiplex PCR including an 
internal control, rpoB 102,115. The PCR was optimised as a touchdown PCR to reduce non-
specific binding (figure 4.4). Carbapenemase genes were not detected in any of the isolates.  
 
Figure 4.4: Multiplex PCR identification of carbapenemase genes. Lanes 1 and 11 contain the KAPA 
universal DNA ladder, lanes 2 to 6 contain the various control isolates. Lane 7 contains combination 
of all controls. Internal control, rpoB, at 1100bp. 
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4. Discussion 
4.1 ESBL characterisation 
A multiplex PCR was used to screen all isolates for the TEM, SHV and CTX-M β-lactamase 
genes; the addition of an internal control, rpoB, ensured that DNA quality was sufficient and 
amplification had taken place, and that the absence of any β-lactamase genes was true and 
not a result of a failed PCR. The addition of this internal control meant further optimisation of 
this PCR which involved increasing the annealing temperature to 67°C. The concentration of 
the SHV primers was also increased slightly to allow for better amplification. Some faint non-
specific bands were observed at 350bp after the internal control was added.  
The majority (86.4%; 121/140) of isolates contained at least one β-lactamase gene. From 
the β-lactamase PCR only, TEM genes are the most common, seen in 87 isolates, followed 
by SHV in 57 isolates and CTX-M in 46 isolates. A study conducted in Pretoria, South Africa 
found overall similar rates of β-lactamase genes; 87% of isolates had β-lactamase genes 120. 
The most common profile observed in their study was TEM, SHV and CTX-M at 36% but the 
level of SHV genes was lower, 4% alone and 12% with TEM in comparison to 16 and 25%, 
respectively, in our study. The isolates studied by Ehlers et al. consisted mainly of K. 
pneumoniae and E. coli (83%) but also included other Enterobacteriaceae, such as 
Citrobacter freundii, Morganella morganii, Enterobacter cloacae and Proteus penneri, which 
may explain the dissimilarity in some results. Alternatively, this may reflect differences in the 
epidemiology between the two settings. The study used the same PCR assay as was used 
in the current study.  
This multiplex PCR is advantageous as it allows for the collective detection of important β-
lactamase genes. This provides important information about the molecular epidemiology of 
these genes. Unfortunately, it does not differentiate between non-ESBL and ESBL TEM and 
SHV genes, which is necessary to determine whether an isolate truly harbours ESBL genes. 
Therefore, all TEM and SHV genes were sequenced so that they could be differentiated into 
non-ESBL and ESBL TEMs and SHVs. It is necessary to investigate whether the genes are 
ESBLs as this will allow better comparison and interpretation of the data, and allow for 
correlation with results of phenotypic testing (which will be discussed in chapter 5). 
Previously, only isolates positive for CTX-M genes could be confidently identified as 
containing ESBL genes. 
The majority of the TEM genes, 98%, were non-ESBL TEM genes, i.e. TEM-1  
(94.2%; 72/86) and TEM-2 (3.5%; 3/86) genes. Therefore, in cases were these genes are 
found alone, these isolates are β-lactamase producers, not ESBL producers. This is 
consistent with the fact that TEM-1 is said to be the most common plasmid mediated β-
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lactamase found in Gram negative bacteria 121. In the two isolates with ESBL TEM genes, 
these genes were found alone, so these isolates were considered ESBL producers. 
Unfortunately, the amplified sequence was too short to further identify these ESBL genes.  
Just under half of the SHV genes (47.4%; 27/57) were those that do not have ESBL activity, 
7% (4/57) of SHV genes were ESBL SHV genes, while the spectrum of activity of 45.6% 
(26/57) of the SHV genes’ is unknown. The most common non-ESBL SHV gene was  
SHV-11 (73.1%; 11/27). A review on SHV genes stated that SHV-11 is the most successful 
non-ESBL SHV variant 113. Only one isolate contained the SHV-1 gene. It was expected that 
the majority of K. pneumoniae isolates would contain the non-ESBL SHV gene, SHV-1, as 
this β-lactamase is commonly harboured on the chromosomes of K. pneumoniae isolates 9. 
It is possible that the isolates may harbour SHV-1 chromosomally in addition to another 
plasmid-encoded SHV gene, which may have been preferentially amplified due to a higher 
copy number. It is unlikely to be clonal expansion of an unusual strain, based on the strain 
typing results in chapter 3. The SHV genes SHV-28, SHV-125, SHV-137 have not yet had 
their phenotype described, and it is unknown whether these genes have ESBL activity or 
not. 
The TEM and SHV sequences used to further identify the genes were only a portion of the 
gene, with the SHV sequence being 747bp and the TEM sequence being only 445bp, while 
the full TEM and SHV genes are over 850bp 58. Having the full TEM and/or SHV sequences 
may have allowed better identification of these genes. The Lahey database was used to 
determine whether SHV genes have ESBL activity or not 53. This database is useful in that it 
shows described TEM and SHV β-lactamase genes and the specific amino acid changes for 
each gene. However, numerous genes have not had their phenotype described so it is 
unknown whether these β-lactamase genes have ESBL activity. To add to the difficulties in 
using the database, some β-lactamase genes have been withdrawn or have more than one 
name. The profusion of research (including the current study) describing old and new β-
lactamases makes curating and maintaining such databases more and more difficult. It is not 
clear whether this database will be updated and if further work is being done to investigate 
the genes that are not fully described.   
Although analysis of the sequencing results was difficult, it did enable the assignment of 
TEM and SHV genes as ESBL or non-ESBL genes, thereby better interpreting the β-
lactamase PCR results. When analysing the β-lactamase PCR and sequencing data 
together, the number of β-lactamase genes found in the isolates are 85 TEM β-lactamase 
genes and 27 SHV β-lactamase genes. The most commonly seen ESBL genes are CTX-M 
(46), followed by SHV (4) and then TEM (2). CTX-M genes were frequently observed in 
combination with other non-extended β-lactamase genes (36/46; 78.3%) as well as with 
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ESBL genes (3/46; 6.5%). Fifty isolates contained at least one ESBL gene, yet only 7 
isolates had CTX-M genes in isolation.  A study on ESBL producing E. coli and K. 
pneumoniae isolates observed co-production of CTX-M genes and other β-lactamase and 
ESBL genes in 81.3% and 97.6% of E. coli and K.  pneumoniae isolates respectively 107. 
Isolates contain multiple β-lactamase resistance genes as this may result in the isolate being 
able to hydrolyse an increased spectrum of antibiotics. β-lactamase TEMs are able to 
hydrolyse first generation cephalosporins, but have less activity against oxyimino 
cephalosporins 59. CTX-M enzymes have greater activity against oxyimino cephalosporins, 
particularly cefotaxime 59. Certain SHV and TEM genes, such as SHV-10 and TEM-103, 
have an inhibitor resistant phenotype, making them resistant to β-lactamase inhibitors such 
as clavulanic acid 58,122. Therefore, a combination of genes may contribute to a bacterial 
strain having resistance to an increased range of β-lactam antibiotics.  A Kenyan study on  
E. coli isolates spanning 18 years, observed β-lactamase genes in combination for 35.3% of 
isolates 122. A study on ESBL producing Enterobacteriaceae in South Africa observed  
β-lactamase genes in combination in 58.5% of isolates 120. Gürntke et al. observed the 
combination of TEM, SHV and CTX-M genes in 57.1% of K. pneumoniae isolates from 
bloodstream infections 123. A study from Syria on the prevalence of β-lactamases in E. coli 
and K. pneumoniae isolates, observed a combination of β-lactamase genes in 64.8% of  
E. coli isolates and 100% of K. pneumoniae isolates 124. 
Other studies focused on E. coli and K. pneumoniae have also reported that CTX-M genes 
are the most commonly found ESBL genes in their setting, although these studies cited 
much higher rates of CTX-M genes in their isolates (67-99.6%) 107,123. A recent review on 
ESBLs stated that CTX-M ESBLs are now the most prevalent ESBLs globally 9. CTX-M 
ESBLs in our study were more often found in K. pneumoniae (78.3%) than E. coli (21.7%). It 
was expected to find more CTX-M ESBLs in E. coli as they are said to be the most common 
hosts of CTX-M genes and the highly successful E. coli clone ST131 frequently harbours 
CTX-M-15 9,77,108.  This may be explained by the fact that in this study E. coli isolates were 
mostly community-acquired while K. pneumoniae isolates were mostly hospital-acquired, 
and the community-acquired isolates did not harbour many ESBL genes (7/47).  
A PCR to further classify CTX-M genes was performed on isolates containing these genes in 
the β-lactamase PCR. This was done to enable comparison to epidemiology in other studies. 
Optimisation of this PCR was more complex as controls were not available. Isolates showing 
amplification of the correct size were sequenced so that they could be used as controls in 
further PCR reactions.  
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Most CTX-M genes (42/46; 91.3%) were classified as group 1. Group 1 contains CTX-M-15, 
the most commonly found CTX-M gene worldwide and is therefore expected to be the most 
common group 9. The obtained results correspond with what has been found in other studies 
in South Africa and other countries 101,111,120,125. Ehlers et al. and Peirano et al. both carried 
out studies in South Africa and found CTX-M genes from group 1 made up 47% and 63.6% 
of CTX-M genes. A study from the United States reported group 1 CTX-M genes made up 
67.7% of CTX-M genes, while a study from Burkina Faso reported 94% of CTX-M genes 
belonged to group 1. One isolate could not be further typed into its specific CTX-M group. 
Singleplex PCRs with each primer set, corresponding to the different CTX-M families, was 
performed on this isolate. The PCR products were sent for sequencing. Although 
amplification was seen emulating group 1, sequencing results could not confirm this.  
Using the combined genotypic information to assign isolates as ESBL or non-ESBL 
producers, 50/140 (35.7%) of isolates contain ESBL genes, 71 (50.7%) isolates contain β-
lactamase genes, 19 (13.6%) contain no β-lactamase genes. Of the 71 isolates containing β-
lactamase genes, 12 of these contain SHV genes for which the spectrum of activity is 
unknown. The ESBL producing isolates are mostly made up of K. pneumoniae isolates 
(39/50; 78%) and the non-ESBL β-lactamase producers are mostly made up of E. coli 
isolates (59/78; 75.6%).  
The prevalence of ESBL genes in our setting is much lower than what is observed in other 
studies from Africa and Asia (65-98%), however these studies only screened isolates that 
were phenotypically ESBL producers for ESBL genes 124,126–128. A study investigating the 
carriage of β-lactamase genes in E. coli isolates collected in Kenya over 18 years, reported 
23.9% of isolates carried ESBL genes and 38.9% of isolates carried β-lactamase genes 122. 
This is lower than what was observed in our study, which may be due to the study including 
various clinical specimens and collection of isolates began in 1992 when carriage of β-
lactamase genes may have been lower.  
When looking at the distribution of β-lactamase and ESBL genes in E. coli and K. 
pneumoniae, two different profiles can be seen. For E. coli isolates, the most commonly 
seen genes are TEM β-lactamase genes alone (44/70; 62.9%), followed by the absence of 
any β-lactamase genes (15/70; 21.4%). A few isolates contained the CTX-M gene alone 
(6/70; 8.6%) and or in combination with TEM β-lactamase genes (4/70; 5.7%). None of the 
E. coli isolates contained SHV genes alone or in combination. Most E. coli isolates (59/70; 
82.3%) have a non-ESBL genotype, while 11 (15.7%) do have ESBL genes. 
In contrast, in K. pneumoniae isolates, the most commonly seen profiles are SHV  
β-lactamase genes (21/70; 30%), the combination of CTX-M and SHV- and TEM-β-
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lactamase genes (21/70; 30%). The remainder of the profiles are seen in a couple of 
isolates. More than half of K. pneumoniae isolates (39/70; 55.7%) harbour ESBL genes, 
while only 31 (44.3%) isolates do not. 
SHV ESBL genes were second most common ESBL genes found in this set of isolates, as in 
other studies 107,123. These genes were commonly seen in K. pneumoniae, yet none were 
detected in E. coli isolates.  A study conducted in Limpopo of South Africa found very similar 
results in their E. coli isolates 129. TEM genes were observed in 95.1% of isolates, CTX-M 
genes were observed in 4.9% of isolates and no SHV genes were detected. Two studies 
from South Africa, covering multiple provinces found that SHV genes were most common in 
K. pneumoniae and observed the combination of SHV, CTX-M and TEM to be the most 
common profile seen in the isolates 57,76. A study using data from SENTRY Antimicrobial 
Surveillance Program in the Asia-Pacific region, also found that TEM genes dominated in  
E. coli isolates, while SHV genes dominate in K. pneumoniae isolates 130. 
4.3 Carbapenemase characterisation 
All isolates were screened for carbapenemase genes. The genes screened for are the most 
clinically relevant and commonly found carbapenemase genes. Two multiplex PCRs were 
merged into one PCR which was further enhanced to include an internal control. 
Optimisation of this multiplex PCR was more complex and was ultimately optimised to a 
touchdown PCR, to reduce non-specific binding.  
No carbapenemase genes were found in the isolates. Likewise, a study conducted in the 
Eastern Cape of South Africa and one conducted across various provinces in South Africa, 
looking at resistance in K. pneumoniae, saw no carbapenemase genes, although these 
studies only screened for NDM and KPC genes 57,76. Carbapenemase resistance in South 
Africa is relatively low, although the absence of any of the carbapenemase genes was 
perhaps surprising as this resistance mechanism is increasing worldwide 4,5. This data does 
however support another (as yet unpublished) study performed at Tygerberg Hospital where 
adult in-patients were screened for rectal carriage carbapenemases and one 
carbapenemase producing isolate was detected out of 439 samples (P. Nel, personal 
communication)  
5. Conclusion 
The presence of β-lactamase genes was observed in 86.4% of the isolates. Just more than 
a third of the isolates (35.7%) contained ESBL genes, 64.3% contained β-lactamase genes 
and 13.6% contained no β-lactamase genes. E. coli and K. pneumoniae showed different 
profiles with TEM β-lactamase genes being most common in E. coli isolates and SHV  
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β-lactamase genes and the combination of CTX-M and SHV- and TEM-β-lactamases in  
K. pneumoniae. Sequencing of the TEM and SHV isolates provided more information about 
the resistance genes. Analysis of the sequencing was difficult as only a portion of the gene 
was sequenced and the databases containing TEM and SHV sequences and information 
about each gene are not complete, especially for the more recently discovered genes. The 
incomplete SHV and TEM database meant that the phenotype of some SHV genes is not 
known. Comparison of the prevalence of ESBL genes found in this study compared to other 
studies can be difficult as it is not always known whether the detection method used by other 
studies discriminates between non-ESBL and ESBL genes. Most of the CTX-M genes were 
from group 1 which is consistent with the literature. No carbapenemase genes were 
observed in the isolates, which is positive for the efficacy of carbapenems in our setting, at 
least for now.  
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Chapter 5: Blending of clinical, resistance and 
epidemiological data 
1. Introduction 
Bloodstream infections (BSIs) are a notable cause of morbidity and mortality worldwide 131. 
Increasing resistance in Gram negative bacteria has made treatment of infections with these 
bacteria increasingly difficult. Infection with resistant bacteria often results in poor clinical 
outcome which may be exacerbated by a delay in treatment with appropriate therapy 132. 
These infections may also result in lengthier hospital stays and increased medical expenses 
12,132.  
The World Health Organisation (WHO) has said that the surveillance of antibiotic resistance 
is the cornerstone for evaluating the burden of resistance and providing the information 
needed to guide action plans regarding antibiotic resistance 133. The WHO has also said that 
Escherichia coli and Klebsiella pneumoniae BSIs are priority specimens and pathogens for 
antibiotic resistance surveillance, as these infections are frequent and have shown an 
alarming increase in resistance, particularly to last resort antibiotics 133.  
Resistance data from previous years can be compared to current data to determine whether 
there are any significant changes in resistance, particularly emerging resistance 
mechanisms such as Carbapenem Resistant Enterobacteriaceae (CRE). This information 
can be used to prevent the spread of concerning resistance mechanisms, although without 
additional clinical data this does not indicate the extent of the problem in the population 133. 
Combining epidemiological, resistance and clinical data will provide a more complete picture 
of the antibiotic resistance problem. Understanding the molecular epidemiology of these 
resistance genes will assist in defining the impact of these resistance mechanisms and help 
to ascertain where infections with resistant bacteria are occurring 101. It will also assist in 
guiding correct empiric treatment and highlight the importance of antibiotic stewardship and 
Infection Prevention and Control (IPC). 
In this section clinical, resistance and epidemiological data from previous chapters was 
combined to better understand E. coli and K. pneumoniae BSIs.  
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2. Materials and methods 
2.1 Statistical analysis 
Statistical analysis was performed with the assistance of the Biostatistics unit from the 
Centre for Evidence-based Health Care at Stellenbosch University. IBM SPSS statistics 
version 25 was used for all statistical analysis. The chi-square test and Mann-Whitney test 
was used to estimate the significance of the correlation with statistical significance defined 
as p<0.05. 
Molecular resistance was defined as isolates harbour at least one Extended-Spectrum β-
lactamase (ESBL) gene; phenotypic resistance was defined as resistance to cefotaxime. 
3. Results and discussion 
3.1 Genotypic versus phenotypic resistance 
Results indicating phenotypic and genotypic ESBL production (chapters 2 and 4) were 
compared. Isolates producing ESBL genes were determined via Polymerase Chain Reaction 
(PCR) and sequencing. Phenotypic ESBL producers were identified by Antibiotic 
Susceptibility Testing (AST) and were considered ESBL producers if they were resistant to 
the third generation cephalosporin, cefotaxime. As discussed in chapter 4, 25 of the 57 
(43.9%) SHV genes have not yet had their phenotype described. There were 12  
K. pneumoniae isolates in which these SHV genes were found alone or in combination with 
a TEM β-lactamase gene, it is unknown whether these SHV genes have ESBL activity or 
not, therefore these isolates were not included in further analysis.  
The genotypic and phenotypic results of 122/128 (95.3%) isolates correlated, with 76 being 
non-ESBL producers and 46 being ESBL producers. Four (3.1%) of the of isolates were 
positive for ESBL genes but did not demonstrate phenotypic ESBL production. Two (1.4%) 
isolates did not contain ESBL genes but were phenotypically resistant to cefotaxime. The 
sensitivity of AST to detect ESBL genes was 92% and specificity was 97.4%. The sensitivity 
was lower than desired due to the four isolates which contained ESBL genes but were 
phenotypically negative for ESBL production. These four isolates include two isolates with 
TEM ESBL genes and two isolates with TEM β-lactamases and CTX-M ESBLs. It is possible 
that the TEM ESBLs may not possess extended-spectrum activity. This is a limitation of the 
analysis for TEM genes, as only a portion of the gene was sequenced it is not known exactly 
which TEM genes these isolates contain. It is unclear why two isolates with CTX-M genes 
would be phenotypically negative for ESBL activity as all CTX-M genes are said to have 
ESBL activity 53. This has also been observed by a study conducted in India, and may be 
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due to the fact that isolates did not express the CTX-M gene or the isolate may be exposed 
to external effects that disrupt the gene 134. Kiiru et al. noted that when OXA-1 and TEM-1 
enzymes are co-produced with CTX-M enzymes, they mask the ESBL phenotype conferred 
by the CTX-M enzymes 122.  The two isolates in this study that were phenotypically ESBL 
negative but contained CTX-M genes, also contained TEM-1 genes, although presence of 
OXA β-lactamases was not investigated in this study, this could be investigated in future 
work. Two isolates harboured TEM ESBL genes but were cefotaxime resistant. This may be 
due to the production of other resistance mechanisms such as AmpC β-lactamases 135.  
The K. pneumoniae isolates containing SHV genes with unclassified phenotype were further 
investigated. Twelve of the 25 isolates contained these genes in the absence of ESBL 
genes. These isolates were not phenotypically ESBL producers, therefore it can be 
speculated that these genes may only have β-lactamase activity. This hypothesis could be 
studied further using enzymatic assays or conjugation experiments with AST.  
One isolate was resistant to the carbapenem ertapenem but did not demonstrate the 
presence of any of the carbapenemase genes that were screened for. This isolate may be 
resistant to ertapenem as a result of other less common carbapenemase genes or due to an 
alternative resistance mechanism, such as reduced porin expression along with the 
production of a β-lactamase with weak carbapenem activity 15,19. Carbapenem resistance 
should be monitored as increasing levels of resistance has been noted in many countries 4.   
3.2 Statistical analysis of patient data and resistance data 
Patient data (chapter 2) and resistance results (chapter 4) were analysed to identify any 
associations. When looking at resistance and outcome, molecular resistance had a slightly 
higher mortality (33.9% vs 26.9%) as did phenotypic resistance (34.0% vs 27.8%). However, 
this difference was not significant and therefore, neither molecular nor phenotypic resistance 
was associated with mortality (p=0.373; p=0.441). While some studies have shown similar 
results, others have found that BSIs with ESBL producing bacteria to have significantly 
higher rates of mortality 16,123. A review on Gram negative bloodstream infections has stated 
that it is not the presence of ESBL producing organisms, but rather the incorrect empirical 
treatment of these infections that results in increased mortality 83. An Italian study on ESBL 
BSIs found that increased mortality was due to inadequate initial antimicrobial therapy and 
failure to identify the source of the infection 38.  Patients that received inadequate initial 
antimicrobial therapy had a mortality rate nearly three times higher than patients who 
received suitable treatment from the start. A study conducted in Tygerberg Hospital on 
paediatric BSIs found antimicrobial resistance was not associated with mortality, but 
attributed this to carbapenems being the empiric treatment option for hospital-acquired BSIs 
Stellenbosch University  https://scholar.sun.ac.za
70 
 
32. Treatment of BSIs caused by ESBL producing organisms with carbapenems, is 
associated with a lower mortality 83. This highlights the need to provide prompt adequate 
treatment to patients and the value of knowledge of the local distribution of pathogens and 
their antibiotic resistance rates.  
Hospital-acquired isolates were associated with molecular resistance (p=0.001) as well as 
phenotypic resistance (p<0.001). A longer time spent in hospital before the blood culture 
was taken was also associated with molecular resistance (p<0.001) and phenotypic 
resistance (p<0.001). Bacterial strains circulating in hospitals are often resistant to antibiotics 
due to the high selection pressure for resistant bacteria resulting from high antibiotic use in 
hospitals. Increased length of hospital stay exposes patients to these resistant strains. 
Increased antibiotic resistance and ESBL production in hospital-acquired isolates was also 
observed in a study conducted at a hospital in Cape Town 17. This highlights the importance 
of determining whether a BSI is hospital- or community-acquired when defining empirical 
treatment options.  
Patients with infections due to phenotypically or genotypically ESBL-positive isolates had a 
slightly longer stay in hospital after the blood culture was taken, although this was not 
significant (p=0.664; p=0.172). Studies have noted increased hospital days due to infections 
with ESBL producing E. coli and K. pneumoniae 136,137. However, Brenner et al. noted that 
only increased length of stay of patients in ICUs was statistically significant. Infection with 
resistant bacteria is expected to result in increased hospital stay due to decreased effectivity 
of antibiotics, delay in appropriate treatment and an increased need for surgery and other 
procedures 136. All these factors also lead to increased cost of care.  
The clinical data obtained was limited and therefore we could not analyse factors such as 
co-morbidities, antimicrobial treatment before and after microbiological results, and 
additional procedures performed on patients. This limited data also meant that we were 
unable to assess potential risk factors for infection with ESBL producing E. coli and  
K. pneumoniae. 
3.3 Strain typing and resistance genes 
As mentioned in chapter 3, the results from both strain typing techniques demonstrate that 
the isolates in this study are genetically diverse, with little clustering seen in both typing 
techniques. This precluded any attempt to associate specific resistance genes or 
phenotypes with specific strains. Phylogenetic trees supplemented with clinical and 
resistance data (chapter 2 and 4) can be found in appendix B (figure B.1-B.4).  
The lack of clustering among isolates suggests that resistance is not being dispersed by 
proliferation of resistant strains, but rather due to the transfer of resistance genes and/or 
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plasmids 16,106.  This hypothesis could be further investigated in future work focussed on the 
resistance plasmids in these isolates. The lack of clustering may be a result of ongoing 
antibiotic selection pressure that has selected for multiple resistant strains which have now 
become endemic in our setting. 
4. Conclusion 
When comparing molecular and phenotypic resistance, 95.3% isolates correlated, 3.1% of 
isolates were positive for ESBL genes but did not demonstrate phenotypic ESBL production 
and 1.4% did not contain ESBL genes but were phenotypically resistant to cefotaxime.  
Mortality was not associated with phenotypic and molecular resistance. Hospital-acquired 
isolates as well as increased stays in hospital before blood culture were associated with 
molecular and phenotypic resistance. Collected patient data was limited and additional 
clinical data may assist in evaluating antibiotic use in our setting as well as risk factors for 
infection with ESBL producing organisms. The genetically diverse isolate collection 
precluded any attempt to associate resistance genes or phenotypes with specific strains.  
Understanding the prevalence of resistant strains in our setting is vital as this will help inform 
empiric therapy. Prompt adequate therapy of infections with resistant bacteria has been 
shown to reduce mortality. Continuous efforts are required to gather information on the 
molecular epidemiology of resistance genes to monitor antimicrobial stewardship efforts and 
ensure correct empiric treatment. Every effort should be taken to preserve the efficacy of 
cephalosporins and carbapenems in particular.   
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Conclusion 
Escherichia coli and Klebsiella pneumoniae are common causes of both community- and 
hospital-acquired bloodstream infections (BSIs). Resistance to commonly used antibiotics, 
such as cephalosporins and carbapenems, threatens the treatment of these infections. 
Resistance to β-lactam antibiotics is often due to the production of β-lactamase enzymes, 
such as Extended-Spectrum β-lactamases (ESBLs) and carbapenemases.  
The aim of this study was to describe the epidemiology of E. coli and K. pneumoniae strains 
isolated from blood cultures at Tygerberg Hospital over a period of one year. Commonly 
observed resistance mechanisms were investigated, and this data was combined with 
clinical and molecular typing data to elucidate the epidemiology and impact of these 
infections.  
Patient and isolate information was collected to determine antibiotic resistance, mortality 
rates and differentiate between hospital- and community-acquired isolates and the shared 
features of these two groups. Two thirds of the collected isolates were hospital-acquired, 
which may be due to the fact that this study took place at a tertiary hospital. The hospital-
acquired isolates were predominantly K. pneumoniae, while community-acquired isolates 
were mostly E. coli. The crude mortality was 30% and BSIs with hospital-acquired isolates 
were not associated with mortality.  
Increased antibiotic resistance was observed in hospital-acquired isolates, particularly to co-
trimoxazole, co-amoxiclav, cefotaxime, ciprofloxacin, gentamicin and piperacillin-
tazobactam. Phenotypic ESBL production was defined as resistance to cefotaxime, which 
was observed in 35.7% of isolates. Phenotypic ESBL production was significantly more 
common in K. pneumoniae isolates (55.7%), compared to E. coli isolates (15.7%). One  
K. pneumoniae isolate was resistant to ertapenem. Increased antibiotic resistance was 
observed in isolates that were cefotaxime resistant (ESBL producer) as compared to 
cefotaxime sensitive isolates, fortunately these isolates remained relatively sensitive to 
amikacin (98%) and ertapenem (98%), which is re-assuring as these antibiotics are often 
used to treat infections with ESBL producing organisms. 
Isolates were typed using rep-PCR and Pulsed Field Gel Electrophoresis (PFGE) to gain 
insight into the epidemiology. Phylogenetic trees generated from the typing results showed 
little clustering, indicating that the isolates were genetically diverse. This was also seen in 
the Simpson’s index of diversity values which were close to 1, indicating that if two isolates 
were randomly selected they would most likely be unrelated. PFGE showed higher 
discrimination, however rep-PCR provides a typing method that is less laborious and time 
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consuming. The diversity of the isolates suggests that patient-to-patient transmission and 
contamination of the environment is not a major source of these organisms. Although this 
result is positive for infection prevention and control in our setting, it does make ascertaining 
transmission routes and implementing interventions to reduce BSIs with resistant organisms 
more difficult. Further studies may be required to investigate this. 
Polymerase Chain Reaction (PCR) and sequencing was used to determine the prevalence 
of β-lactamases and carbapenamases in the collected isolates, and to further characterize 
the types present. The multiplex β-lactamase PCR identified β-lactamase genes in 86.4% of 
the isolates. TEM and SHV genes were further characterised by sequencing. The majority 
(98%) of TEM genes were narrow-spectrum β-lactamase TEMs, i.e. TEM-1 and TEM-2, 
while 2% were ESBL TEMs. Just under half of the SHV genes (47.4%) were narrow 
spectrum β-lactamase SHV genes, 7% were ESBL SHV genes, while the spectrum of 
activity of 45.6% of the SHV genes is unknown. These genes have not yet had their 
phenotype reliably described and it is not known whether they have an extended-spectrum 
of activity or not. 
The majority of the CTX-M genes (91.3%) were classified as group 1 CTX-M’s, which 
contains the most commonly found CTX-M gene worldwide, CTX-M-15. No carbapenemase 
genes were detected in any isolates. South African studies on the prevalence of 
carbapenemase genes have detected low frequencies of these genes as compared to 
studies in other countries.  
Based on PCR and sequencing data, 35.7% of isolates contained ESBL genes, 50.7% 
contained narrow-spectrum β-lactamase genes and 13.6% of isolates were negative for  
β-lactamase genes. The most common ESBL gene was CTX-M, which was frequently 
detected in combination with other ESBL (6.5%) and β-lactamase genes (78.3%).  
Phenotypic ESBL production (cefotaxime resistance) was compared to molecular detection 
of ESBL genes; the results correlated for 95.3% of isolates. Interestingly, two isolates 
containing CTX-M genes were phenotypically cefotaxime susceptible, this may be due to the 
gene not being expressed. This could be investigated further in future work. Twelve  
K. pneumoniae isolates harboured one or other of the SHV genes with unclassified 
phenotypes, in the absence of any other ESBL gene. These isolates were all susceptible to 
cefotaxime, suggesting that these genes may not be able to hydrolyse extended-spectrum 
beta lactams such as third generation cephalosporins. This hypothesis could be investigated 
further by enzymatic assays and/or conjugation studies combined. 
Statistical analysis of clinical and resistance data was performed to determine whether there 
was a correlation between results. Mortality was higher in patients with isolates 
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phenotypically (34% vs 27.8%) or genotypically (33.9% vs 26.9%)) positive for ESBLs, 
although this was not statistically significant. Hospital-acquired isolates and longer stays in 
hospital before blood culture was taken were associated with the presence of ESBLs. This is 
not surprising as high antibiotic use in hospitals selects for resistant bacterial strains. 
Infection with resistant bacteria was not associated with increased length of hospital stay. 
Studies have suggested that mortality due to infection with resistant organisms is due to 
inappropriate empiric therapy, which highlights the importance of local epidemiological data 
and surveillance of antibiotic resistance.  
Unfortunately, the patient information collected in this study was limited and cause of death, 
co-morbidities of patients and previous antibiotic use were not known. This information may 
assist in evaluating risk factors for bloodstream infection with ESBL producing bacteria. 
Obtaining information about treatment before and after laboratory results will assist to 
evaluate empiric treatment and whether antibiotic treatment is adjusted according to 
bacterial species and resistance information. The finding that the mortality rate for 
cefotaxime resistant and susceptible isolates was not statistically different may indicate that 
the local empiric regimen for hospital-acquired infections (which were associated with the 
resistant phenotype) is appropriate. However, this assumption needs to be tested more 
thoroughly, and a prospective study collecting both treatment and outcome data, as well as 
data from uninfected controls, is underway. 
Strain typing revealed the E. coli and K. pneumoniae isolates at Tygerberg Hospital to be 
genetically diverse. The lack of clustering precluded any attempt to associate specific traits 
with particular strains. The diversity of strains harbouring β-lactamase genes suggests that 
resistance may be due to the transfer of resistance genes and/or plasmids. Further studies 
could investigate this hypothesis and enable a better understanding of the transmission 
dynamics of resistant organisms, which may assist in focusing Infection Prevention and 
Control (IPC) efforts.  
Continuous efforts are required to investigate the epidemiology of circulating strains and 
their resistance patterns to monitor antimicrobial stewardship efforts, guide action plans and 
ensure correct empiric treatment. It is pertinent that the efficacy of cephalosporins and 
particularly carbapenems are preserved as far as possible.  
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Appendix 
Appendix A 
Table A.1: Distribution of β-lactamase and ESBL genes in E. coli and K. pneumoniae isolates. 
 
Appendix B 
Phylogenetic trees of E. coli and K. pneumoniae for rep-PCR and PFGE, supplemented with 
clinical and resistance information. Phenotypic resistance refers to resistance to cefotaxime. 
Key: M = Male; F = Female; HA = Hospital-acquired; CA = Community-acquired; S = 
Susceptible; R = Resistant; TEM-E =TEM gene with extended-spectrum activity (ESBL); 
SHV-N = SHV without extended-spectrum activity; SHV-E = SHV with extended-spectrum 
activity; SHV-U = SHV with uncertain extended-spectrum activity.  
 E. coli K. pneumoniae Total 
TEM β-lactamase only 44 1 45 
TEM ESBL only 1 1 2 
SHV β-lactamase only 0 21 21 
SHV ESBL only 0 0 0 
CTX-M only 6 1 7 
CTX-M, TEM β-lactamase 4 6 10 
SHV β-lactamase, CTX-M 0 6 6 
SHV ESBL, CTX-M 0 0 0 
SHV β-lactamase, TEM β-lactamase 0 5 5 
SHV ESBL, TEM β-lactamase 0 2 2 
SHV β-lactamase, CTX-M, TEM β-lactamase 0 21 21 
SHV ESBL, CTX-M, TEM β-lactamase 0 2 2 
None 15 4 19 
 70 70 140 
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Figure B.1: Phylogenetic tree generated from rep-PCR results for E. coli isolates, supplemented with 
clinical and resistance data.  
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Figure B.2: Phylogenetic tree generated from rep-PCR results for K. pneumoniae isolates, 
supplemented with clinical and resistance data.  
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Figure B.3: Phylogenetic tree generated from PFGE results for E. coli isolates, supplemented with 
clinical and resistance data.  
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Figure B.4: Phylogenetic tree generated from PFGE results for K. pneumoniae isolates, 
supplemented with clinical and resistance data.  
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